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Summary  
 
Rewired cancer metabolism sprang into the spotlight this century as a crucial aspect 
of the malignant transformation. Being the century of the DNA, most 20th century 
cancer research focused on approaching cancer as a direct result of accumulated 
mutations while overlooking the metabolic aspects. Albeit very insightful on the origin 
of the disease, this approach has fallen short of eradicating cancer. Hence efforts in 
oncology research embarked on exploring other aspects in a bid for a whole-rounded 
anti-cancer approach. Consequently, last decade has seen accelerating 
breakthroughs in elucidating the metabolic adaptation of cancer cells to provide the 
requirements of rapid proliferation and the implication thereof as potential drug 
targets.  
Basic metabolic networks and enzymes show large degree of evolutionary 
conservation between eukaryotes. Moreover, yeast and cancer share the major 
metabolic hallmark of aerobic glycolysis, demonstrate comparable proliferative 
tendencies, comparable cell cycle regulation and also undergo apoptosis akin to 
higher eukaryotes. This multiple overlap makes yeast an attractive model for 
addressing glucose metabolism as a driver for rapid proliferation.  
This thesis features the results of my investigation into the regulation and effects of 
the key gluconeogenic enzyme fructose 1,6 bis-phosphatase Fbp1 in two distinct 
eukaryotic systems: the budding yeast Saccharomyces cerevisiae and human breast 
cancer cell lines. Based on previous research pointing out links between Fbp1 and 
the particular type of DNA damage elicited by methyl methanesulfonate. When 
exposed to MMS, Fbp1 is transcriptionally upregulated as a part of the response to 
DNA methylation. Fbp1, on the other hand, bestows an increased MMS-sensitisation 
upon yeast. I devised a mutational analysis of evolutionary conserved residues to 
address the mechanism of this additional phenotype, the results of which 
demonstrated that the enzymatic activity could also be decoupled from further MMS 
sensitisation, hence suggesting a non-catalytic origin of the additional effect.  
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I then embarked on investigating the effects of Fbp1 in breast cancer cell lines of 
both luminal and basal-like lineages. The findings I present make the case for an anti 
proliferative role of Fbp1 as an outcome of diminished glucose sensitivity, uptake and 
a shift from glycolysis to higher mitochondrial activity. Moreover, Fbp1 exhibited a pro 
oxidative role in cell lines manifested in increased ROS accumulation and sensitivity 
to oxidative agents. My findings also provide transcriptional evidence of a Wide - 
scale cell-cycle inhibitory outcome of Fbp1 ectopic expression in Fbp1-deficient 
MDA-MB231. Intriguingly, I observed that Fbp1-deficient basal like breast cancer 
cells acquired the capability to post-transcriptionally breakdown ectopic Fbp1 upon 
long-term stable over-expression. I also demonstrated that this degradation occurs 
through the proteasome and exclusively upon the long-term selection of cells with 
ectopic Fbp1. 
An overview indicates multiple similarities of Fbp1 effects in yeast and cancer cell 
systems. In general, Fbp1 has comparable effects on proliferation, glycolysis, and 
Redox balance in both systems. The proteasomal degradation of Fbp1 in cells draws 
another parallel to the regulation of this enzyme in yeast since the so called 
“catabolite degradation” of Fbp1 had been long described and well-studied in yeast.   
Nevertheless, when compared, the two corresponding mutations in yeast and human 
Fbp1 had distinct consequences for catalytic activity and enzyme stability in each 
system., therefore hinting at structural differences in the activation mechanisms and 
at different interaction partners in the two systems.  
Altogether, the results presented in this thesis endorse Fbp1 as a quasi tumour 
suppressor and emphasise the potential therapeutic significance of approaches that 
can de-repress Fbp1 in cancers lacking it and prevent its ablation in cancers that 
express it.  
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Zusammenfassung 
 
Im letzten Jahrhundert gehörte Stoffwechselwandel in Tumoren zu den wichtigsten 
erforschten Aspekten der malignen Transformation. Im letzten Jahrhundert wurde 
Krebs hauptsächlich als direktes Ergebnis der Akkumulation bestimmter Mutationen 
betrachtet, während die Regulation des Metabolismus der Krebszellen zum größten 
Teil übersehen wurde. Obwohl die Mutationstheorie essentiell für das Verständnis 
der Tumorentstehung ist, reicht sie nicht aus, um den Krebs vollständig zu vermeiden 
oder auszulöschen, aus diesem Grund hat sich Krebsforschung auf andere Aspekte 
fokussiert, um ein ganzheitliches Vorgehen gegen Krebs zu ermöglichen. Aufgrund 
der schnellen Profliferation benötigen Tumore einen reprogrammierten Stoffwechsel, 
um die essenziellen Bausteine und die Energie für das schnelle Wachstum zu 
besorgen.  
Die zentralen metabolischen Wege sind in allen Eukaryoten evolutionär konserviert 
Ferner haben sowohl Tumore als auch eukaryote Mikroorganismen, wie z.B. 
Saccharomyces die Tendenz zur aeroben Glykolyse und schnelleren Proliferation. 
Zudem zeigen beide eine vergleichbare Regulierung des Zellzyklus und Apoptose. 
Aus den oben genannten Gründen bietet Saccharomyces cerevisiae ein einfaches 
zelluläres Model für die Untersuchung von schnellen Proliferation in Beziehung zur 
aeroben Glycolyse (Warburg Effekt).  
In dieser Doktorarbeit stelle ich die Ergebnisse meiner Forschung dar, über die 
Regulation und Wirkungen des Enzyms Fruktose-1,6-bisphosphatase in zwei 
unterschiedlichen eukaryotischen Systemen; i) die Bierhefe Saccharomyces 
cerevisiae und ii) humane Brustkrebszelllinien. 
Ergebnisse bisheriger Forschung an S. cerevisiae haben Zusammenhänge zwischen 
Fbp1 und den von MMS verursachten DNA-Schäden gezeigt. Eine MMS-Behandlung 
induziert die Transkription von Fbp1. Die verstärkte Expression von FBP1 wiederum 
steigert die Empfindlichkeit gegenüber der MMS-Behandlung. Um den Mechanismus 
dieser neuen Funktion des Fbp1-Enzyms zu erforschen, habe ich ein Mutagenese-
   iv 
Screening von evolutionär konservierten Aminosäuren mit struktureller und 
funktioneller Relevanz entworfen. Durch die Mutagenese habe ich die Möglichkeit 
nachgewiesen, die FBPase- Katalyse von der MMS- Sensitivierung zu entkoppeln. 
Weiterhin habe ich die Funktionen von Fbp1 in Brustkrebs-Zelllinien mit einem 
basalen oder ductalen Ursprung untersucht. Allgemein zeigen meine Ergebnisse eine 
antiproliverative Wirkung von Fbp1 als Folge von abnehmender 
Glukoseempfindlichkeit und -aufnahme sowie inhibierter Glykolyse  
Ferner wirkt Fbp1 pro-oxidativ in den untersuchten Zellen, da vermehrt ROS und eine 
erhöhte Empfindlichkeit gegenüber oxidierenden Einflüssen beobachtet werden. 
Dazu weisen meine Ergebnisse auf eine FBP1-verursachte Zellzyklus Inhibierung 
hin, wie eine weitreichende Herabregulierung der Transkription mehrerer 
Zellzyklusfaktoren nach Fbp1-Überexpression in MDA-MB231 Zellen.  
Interessanterweise habe ich einen bisher unbekannten proteasomalen Abbau der 
Fbp1 in MDA-MB231 Zellen bewiesen. Ein ähnlicher Mechanismus ist für S 
cerevisiae bereits gut beschrieben.  
Trotz unterschiedlicher Effekte zweier überlappender Mutationen in Human und Hefe-
Fbp1-Orthologen, die zu signifikanten strukturellen Unterschieden führen, beweist 
diese Arbeit mehrfachlich die Ähnlichkeit in der Regulierung und metabolische 
Wirkung von Fbp1.  
Allgemein unterstützen meine Ergebnisse eine vermutete Tumoursupressor-Wirkung 
für Fbp1 und zeigen somit eine mögliche therapeutische und präventive Relevanz für 
die De-repression und Aktivierung dieses Enzyms im Kontext mit Krebs. 
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JC-1: 5,5,6,6-Tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbocyanine iodide 
kRas: Kirsten Rat sarcoma viral oncogene 
LDH2: Lactate Dehydrogenase 2 
MMS: methyl methanesulfonate 
mTOR: mammalian Target of Rapamycin 
NaCl: natrium chloride 
NADH: Nicotinamide adenine dinucleotide (Reduced) 
NAD+: Nicotinamide adenine dinucleotide (Oxidised) 
NADPH: Nicotinamide adenine dinucleotide phosphate (Reduced) 
NADP+: Nicotinamide adenine dinucleotide phosphate (Oxidised) 
OD: optical density 
OE: over-expression 
OXPHOS: oxidative phosphorylation 
PBS: Phosphate-Buffered Saline 
PDK: Pyruvate Dehydrogenase Kinase 
PEG: polyethyline glycole 
PFK1: Phosphofructokinase1 
PFK2: Phosphofructokinase2 
PGI: Phosphu-gluco isomerase 
PPP: Pentose Phosphate Pathway 
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I- Introduction   
 
“Biologists must constantly keep in mind that what they see was not designed but rather 
evolved”. Francis Crick 
 
I-I Glucose as the main hub of cellular carbon metabolism  
Simplistically speaking, accessible energy and building blocks of macromolecules are 
the two very essential prerequisites of survival and expansion of living cells. 
Metabolism provides the interactive and readily responsive network that connects 
and diverts the flow of energy and matter within the cell according to its needs and 
priorities. Hence, a fully differentiated non-dividing cell e.g. a neuron or a muscle cell, 
has its metabolism wired for optimised respiration, and ATP production to maintain its 
continued integrity and energy-demanding specific function. Whereas rapidly 
proliferating cells e.g. a developing embryo [1], a tumour or a unicellular organism 
exhibit completely different metabolic priorities [2], which reflect in their metabolism 
tilting towards anabolism to create the necessary macromolecules for the daughter 
cells [3]. However, a secure energy flux is still needed for maintaining glycolysis, 
anabolic processes and intracellular homeostasis [4, 5].  
Carbon is the building block of life as we know it [6], it is also the main floating source 
of energy and biomaterial in the ecosystem [7], and in the extracellular compartments 
of multicultural organisms [8]. Extracellular energy floats in form of covalent carbon 
bonds, and is then converted by the cells into more readily accessible phosphate-
bond energy. The larger the carbon-based molecule is, the more steps it needs to be 
broken down to readily catabolisable blocks, hence larger carbon molecules including 
fat play the role of energy storage. Glucose, however, is in the central intersection of 
carbon based anabolism and catabolism, initial intracellular phosphorylation by 
hexokinases at C6 traps glucose within the cell [9], and renders it available for a 
plethora of different pathways depending on the momentary requirements of the cell 
[10]. Glycolysis is the main initial catabolic pathway of glucose, providing pyruvate for 
the TCA, nevertheless it is also the stem, from which the synthetic pathways of 
several amino acids branch, making it a necessary entry step for protein anabolism 
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[11, 12]. The output of full glycolysis is 2 molecules of pyruvate and 4 molecules of 
ATP, pyruvate is either fermented into lactate, converted into aliphatic amino acids or 
further decarboxylated to form Ac-CoA the entry molecule of the TCA, which allows 
the complete decomposition of the remaining carbon bonds and the conversion of 
their energy into ATP and reductive equivalents; NADH and FADH2 [13]. The TCA is 
also the source of the precursors for denovo fatty acid synthesis and the synthesis of 
various amino acids.  
In the aforementioned regard, glycolysis is seen as a central rate determinant for 
cellular energy production, anabolism and consequently proliferation. Besides 
glycolysis, G6P can undergo an alternative catabolic fate through the pentose 
phosphate shunt. The latter is a more specifically anabolic pathway fuelling growing 
and dividing cells with much needed ribose for de-novo nucleotide synthesis, and 
NADPH the main anabolic source of reductive equivalents needed for the synthesis 
of lipids required for all cellular membranes[14]. The pentose phosphate shunt is also 
an essential anti-oxidant pathway, which allows the cells to maintain their reducing 
equivalents to counter redox imbalance and maintain a strongly reductive cytosole 
[14, 15]. Consistently, the pentose phosphate pathway is induced in proliferative and 
anabolic programs, including by aberrantly over activated oncogenes in tumours (e.g. 
mTOR, kRas) [16, 17], whereas tumour suppressors (e.g. p53, AMPK) inhibit this 
pathway [18, 19]. While cells can break down glucose via glycolysis, 
gluconeogenesis enables the intracellular synthesis of glucose starting from TCA-
derived precursors [20]. Since Glucose-6-phosphate is the entry molecule to the 
essential pentose phosphate shunt, it follows that even in energy abundant situations 
minimal levels of glucose-6-phosphate remain indispensable to secure enough PPP 
flux to maintain RedOx homeostasis and fuel de-novo nucleotide synthesis. This 
makes gluconeogenesis absolutely important for cell survival in absence of 
extracellular glucose sources. Despite its importance in glucose absence, when 
glucose is abundant, gluconeogenesis can be very disruptive to cellular metabolism 
due to energy consuming futile cycles. Therefore, the flux through both glycolysis, 
and gluconeogenesis are tightly regulated. In higher organisms including humans this 
regulation is achieved via pancreatic and hepatic hormones that reflect the glucose 
availability in the circulation.  
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I-II PFK1 and Fbp1; the evolutionary conserved gauges of glucose 
consumption and production 
1. Regulation in mammals:  
Glycolysis and gluconeogenesis share most of their enzymes, these catalyze 
reversible reactions according to substrates availability. The two pathways diverge in 
4 steps that are catalyzed by enzymes unique for each pathway [21]. This allows the 
separate regulation of each pathway to avoid futile cycling[22-24].  
Since most intracellular glucose is kept in a phosphorylated state followed by 
reversible isomerisation to fructose 6 phosphate, the following step in glycolysis is 
decisive to the flux through glycolysis as a whole. The second phosphorylation of 
glucose is catalyzed by phosphofructokinase (PFK1), this enzyme is specific for 
glycolysis, and it sets the rate of the pathway as a whole [25, 26]. PFK1 is 
allosterically regulated by a multitude of factors guaranteeing that glycolysis rate is 
adjusted according to cells’ requirements [25, 27, 28]. The reverse step of the second 
phosphorylation of glucose is the dephosphorylation of fructose-1,6-bisphosphatase 
regenerating fructose-6-phosphate and inorganic phosphate. This step constitutes 
the main bottleneck in the gluconeogenesis pathway, and is catalyzed by the rate 
limiting enzyme fructose 1,6 bisphosphatase FBP1 [29]. A kin to PFK1, FBP1 is 
subject to complex allosteric regulation in mammals. The plethora of allosteric 
regulators work on PFK1 and FBP1 in an opposite manner, the abundance of 
glycolytic products citrate and ATP convey a signal of saturation onto the glycolytic 
pathway by inhibiting PFK1 in a classic negative feedback mechanism in which final 
products of pathways inhibit key enzymes of these pathways [30, 31]. Meanwhile the 
abundance of energy (low AMP concentrations) [32], and TCA intermediates (citrate) 
has an indirect permissive effect of gluconeogenesis to allow cells to make use of the 
high energy in anabolism and energy storage in more stable forms including 
glycogen [33]. In addition to direct intracellular factors PFK1 and FBP1 are also under 
the control of the glucose homeostasis hormones, insulin and glucagon. The former 
is an anabolic hormone secreted upon feeding and increasing blood glucose levels, 
and the latter is a catabolic hormone secreted in fasting periods. This hormonal duet 
maintains blood glucose levels within a physiologically tolerable range, and it does so 
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in part via regulating glycolysis and gluconeogenesis [34]. The effects of insulin and 
glucacon oppositely diverge on PFK1 and FBP1 via regulating an intracellular switch 
consisting of a dual-function enzyme phosphofruktokinase2/ fructose-2,6-bis-
phosphatase PFK2/F2,6BPase [34, 35]. During fasting glucagon favours 
gluconeogenesis by indirectly deactivating the PFK2 function and maintaining the 
F2,6BPase function, which in turn depletes F2,6bP leading to increased 
gluconeogenesis flux via lifting the allosteric inhibition of F2,6bp and down regulated 
glycolysis via the lack of allosteric activation of F2,6bP on this enzyme[27, 36].  
In summary, FBP1 and PFK1 constitute the two most important major switches of 
gluconeogenesis and glycolysis respectively and they integrate regulatory signals 
that inversely affect these two pathways to meet both the specific demands of the cell 
and those of the whole organism. It is also worth mentioning that while glycolysis is a 
ubiquitous pathway in all cells, albeit at markedly different rates, gluconeogenesis is 
restricted to certain specialised organs and tissues including the liver, where 
gluconeogenesis is instrumentalised to meet the glucose demands of the whole 
organism and maintain homeostasis.  
 
2. Regulation in unicellular organisms: 
Unicellular organisms, on the other hand, are hard wired to use any environmental 
abundance to achieve faster proliferation and therefore dominate their environment. 
Hence unicellular metabolism is wired to support rapid proliferation, in the case of S. 
cerevisiae and many other eukaryotes and prokaryotes. This means maximizing the 
glycolytic flux with most of the resulting pyruvate being fermented to ethanol or 
lactate. Through largely avoiding respiration, cells can secure maximized glycolysis 
without reaching energy saturation. This allows maximal glucose uptake and 
incorporation of glycolytic intermediates as building blocks to support anabolism 
resulting in fast production of macromolecules important for fast respiration. To 
achieve this, yeast among many other organisms uses glucose itself as the main 
signal steering their metabolism. Glucose repression transcriptionally prevents the 
expression of respiration and gluconeogenesis genes, including fructose 1,6 
bisphosphatase. As mentioned earlier, it is pivotal to down regulate gluconeogenesis 
while glycolysis is active in order to avoid futile cycling. While higher organisms 
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achieve this via posttranslational allosteric regulations, unicellular organisms respond 
directly and readily to glucose queues on a transcriptional level. Besides 
transcriptional control, glucose replenishment also mediates the immediate 
degradation of FBP. Altogether, FBP1 is expressed and degraded on demand in 
unicellular organisms, whereas mammalian cells required to perform 
gluconeonenesis maintain constant levels of the alosterically-regulated protein.  
I-III Contrasts between unicellular and multicellular metabolism control  
The fundamental differences in metabolism between unicellular organisms and 
differentiated cells in higher organisms are attributed to having different objectives to 
be met for securing selective evolutionary advantage for the organism [37, 38]. The 
survival of a unicellular organism is majorly dependent on its fitness and superiority in 
direct competition against other organisms (members of the same species or other 
species) for the nutrients in the environment. Whilst the survival of a multi-cellular 
organism is rather dependent upon the successful cooperation of differentiated cells 
to maintain the organism’s homeostasis and sustain efficiency on the systemic level 
of the organism as a whole [39]. Therefore, the regulation of metabolic pathways 
including glucose and general carbon metabolism is determined by the requirements 
of the organism and differs between tissues and organs depending on their role and 
specific metabolic requirements. Similar considerations underpin the regulation of cell 
proliferation and differentiation in a multi-cellular organism. 
The interplay of intracellular cell cycle regulation and extracellular biochemical 
queues (hormones, growth factors) keeps cellular proliferation under control so that 
the growth and regenerative requirements are met while excessive aberrant 
proliferation is avoided, the immune system also functions as a second line of 
defence by obliterating any cells that seem to defy this control.  
 
I-IV Metabolic reprogramming in cancer: parallels to unicellular metabolism.     
(A regressive fall back onto an ancient and selfish metabolic programme) 
Cancer is in part the result of a failing multicellular homeostatic control and defence 
[40]. In the course of their malignant transformation, cancer cells escape all 
intracellular checkpoints (e.g cell cycle, DNA integrity checkpoints) [41] and 
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extracellular gauges [42] (e.g. reliance on growth signals and hormones, vigilance of 
the immune system) and limitations (e.g. energy supply and molecular substrate) on 
their proliferation, and proceed to acquiring traits that favour their own proliferation on 
the expense of the organism as a whole [43, 44]. The more the deviation from the 
natural differentiation line the worse the prognosis [45]. In this light, cancer can be 
described as a rebellion of a single cell and its transformed lineage against the 
multicellular harmony that reigns over differentiated tissues and organs [46-48]. 
Intriguingly, cancer cells also seem to revert to a metabolic program similar to that of 
unicellular organisms. It is well established that cancer cells undergo metabolic 
reprogramming shifting their reliance from TCA and OXPHOS towards glycolysis as a 
primary pathway for ATP production under aerobic conditions [49-51]. Hypoxia 
inducible factor Hif1a is one major player fostering this metabolic shift [50]. Several 
upstream regulators involved in the abnormal stabilization of Hif1α subunit in 
normoxic conditions are evolutionary conserved between yeast and mammals, these 
include mTOR/TOR1, AMPK/SNF and the oncogene AKT/Scf9 [50-52]. In addition to 
the generally up-regulated glycolysis, tumors have different predominant isozymes 
catalyzing some of the glycolytic reactions, including Glut1, HK2, and PKM2. These 
enzymes show similarities in their regulation specifications and overexpression levels 
to those of the yeast glycolytic pathway [51]. This also holds true for the TCA, which 
gets repressed through inhibition of its entry enzyme PDH, whose activity is 
quenched due to HIF1a-mediated over- expression of PDK [50]. HIF1 also induces 
the overexpression of LDH2, a highly active isoform of lactate dehydrogenase 
rendering cancerous cells into aerobic fermenters akin to unicellular organisms[53]. 
All these similarities point to a “devolution” undergone by malignantly transformed 
cells, in which a single-cell fixated evolutionary-rooted metabolic program overwrites 
the metabolic preferences defined by the multicellular context of differentiated cells 
[46, 47]. Indeed, there are evolutionary views that suggest an independent phylogeny 
of cancers placing them in a separate place of the evolutionary tree from the 
organisms, in which they arise [40, 54].  
 
I-V Cancers down regulate gluconeogenesis: metabolic and proliferative 
advantages 
Introduction 
  7 
Aerobic glycolysis might seem less energetically efficient, but it is only so when 
considering a scarce amount of glucose is available, this limitation is overcome by 
the multicellular physiological condition that provides a continuous supply of 
glucose[55]. Cancer cells rewire their metabolism to give optimal support for their 
accelerated proliferation, this also includes discarding any inefficient pathways whose 
energetic cost can burden the cell and hold back its growth and proliferation [2, 56]. 
Gluconeogenesis is one example of the aforementioned costly pathways; it exists to 
ensure that the organism as a whole averts deleterious hypoglycemia during fasting 
and intense activity[57]. However, for individual cells, gluconeogenesis is less 
efficient compared to taking up glucose and funnelling it through glycolysis. Cancer 
cells particularly enhance their glucose uptake capacity by upregulating the 
expression and membrane localization of glucose transporters[58]. Considered with 
the fact that circulation offers a constant supply of glucose, high capacity of glucose 
uptake enables cancer cells to have a constant abundance of glucose, which would 
render gluconeogenesis obsolete as long as cells receive enough blood supply.   
Indeed, evidence from various tumour types indicates that cancerous cells abandon 
gluconeogenesis mostly by epigenetically silencing fructose 1,6 bis-phosphatase [59-
64]. FBP1 is a rate limiting and key enzyme for this pathway, and silencing amounts 
to a complete shutdown of gluconeogenesis. Liver tumours exhibit drastic epigenetic 
silencing of FBP1. Very recently, the derepression of FBP1 in hepatocellular 
carcinoma HCC cell lines successfully suppressed glycolysis and reversed the 
tumour metabolic reprogramming. In renal clear cell carcinoma, FBP1 repression is 
indispensable for the initial tumorigenesis and malignant transformation. Breast 
tumours vary in regard to FBP1 expression. FBP1 is highly expressed in primary 
luminal breast cancers with relatively good prognosis. While it is absent in basal-like 
breast cancers, including the triple negative breast cancers, all usually exhibit dire 
prognoses. Metastases from FBP1-positive breast tumours also lack FBP1, 
consistent epigenetic repression of FBP1 was observed as part of the EMT-program 
conferring further aggressiveness, invasive and metastatic traits to breast cancerous 
cells. Intriguingly, the ectopic introduction of FBP1 was enough to prevent Snail-
induced EMT; this suggests that FBP1 loss is an essential step for EMT to occur. 
The knockdown of FBP1 in originally FBP1-positive ductal breast cancer cells 
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correlated to increased glycolytic flux, more colonies in culture and larger xenograft 
tumours. Consistently, the ectopic expression in FBP1 in basal like “triple negative” 
cell lines partially reversed the glycolytic phenotype and halted back growth, colony 
and tumour formation. Taken together the aforementioned results suggest a decisive 
role for FBP1 in determining the prognosis and outcome of breast cancers. Unlike in 
other types of cancer where FBP1-loss occurs early during tumour initiation, in breast 
cancer FBP1-repression commences in later stages of tumour development, 
acquisition of invasiveness and metastasis. This makes breast cancers a good model 
for understanding the roles of FBP1 in the context of cancer, in part because a better 
understanding could hopefully reveal novel ways of targeting the more aggressive 
FBP1-negative tumours, or even more ambitiously prevention of reverse the steps 
that lead to FBP1-repression in the first place.  
 
I-VII DNA damage in cancer initiation, treatment and relapse 
The discovery of the DNA as the genomic material and the elucidation of the genetic 
code[65, 66] heralded an understanding of cancer as an outcome of accumulated 
mutations that result from genomic instability[67, 68]. According to the somatic 
mutation theory, cancer initiation and progression occurs by evading various 
constraints of uncontrolled proliferation. To achieve this, cancerous cells and tumours 
as a whole need to acquire 6 malignant hallmarks, this happens as outcome labile 
genome and accumulated mutations[44, 69]. This model of cancer origin and 
progression provided an ample framework for understanding the mechanism of anti-
cancer cytotoxicity of early discovered chemotherapies. The genomic instability of 
cancers, in addition to the continuous rapid proliferation renders cancer cells more 
sensitive to chemicals directly damaging the DNA or inhibiting nucleotide synthesis 
essential for DNA repair and replication[70, 71]. In spite of its decisive effect upon 
cancer treatment for decades to come, chemotherapy confronted the big challenge of 
relapse and resistance emerging in a vast majority of cases. Soon it became clear 
the heterogeneity of cancers meant that treatment resulted in a positive selection of 
more resisting cells. Moreover, the degree of DNA damage nec resulted in a 
selection of DNA damage necessary for killing the majority of tumour cells leaves an 
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amount of surviving cells with increased mutation rate enough for new resistant 
phenotypes to arise[72]. This paradox of DNA damage being both at the root of 
cancer and its basic treatment necessitates wider approaches targeting cancer cells 
beyond the genome. In addition to a plethora of upstream resistance mechanisms 
that depend on limiting the bioavailability of the drug within tumour cells[73], new 
molecular mechanisms have been discovered that rely on modulating the reaction of 
cancer cells to the treatment and hence evade cell death. These include the induction 
of DNA repair pathway, which requires active metabolism generating the necessary 
nucleotides and ATP molecules for DNA repair[74]. Other downstream resistance 
manoeuvres, to which metabolism also contributes, include changed cell cycle 
regulation, apoptosis inhibition, induction of morphological alteration and autophagy 
[72, 75, 76].  Therefore targeting cancer metabolism has emerged as a promising 
anti-cancer approach to target metabolic weaknesses in order to improve response 
and prevent relapse[3]. Therefore, understanding the interaction between different 
metabolic pathways and the responsiveness to various anticancer treatments is 
essential for development of treatment regimens combining both conventional and 
metabolism-targeting agents. In my thesis I further explore the relation between the 
regulation of gluconeogenesis as a result of various Fbp1 contexts and the sensitivity 
of rapidly proliferating cells to DNA damaging agents and other oxidative and 
metabolic cytotoxic treatments.    
I-VII-I Premise, rationale and envisaged objectives 
This thesis features my PhD research focusing on Fructose1,6 bis phosphatase and 
its effects in two distinct contexts; the dual role of FBP1 in the budding yeast 
S.cerevisiae on the one hand, and the metabolic, proliferative and phenotypic impact 
of FBP1 in breast cancer cell lines, on the other. The seemingly unconventional 
approach aims at drawing conclusions from the investigation of FBP1 in yeast that 
can be put into use to improve our understanding of the multiplex effect of this 
enzyme in cancerous cells. As mentioned above, there are several stark similarities 
in metabolic phenotypes and preferences between unicellular organisms and 
cancers. These make it plausible to harness the simplicity of unicellular organisms to 
model and probe certain aspects of tumour metabolism. Various considerations make 
yeast attractive to probe FBP1 in yeast; some are general advantages connected to 
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yeast as a model including its very well defined and easy to manipulate genome, 
yeast have a very fast growth and proliferation compared to mammalian cells and 
wide range evolutionary conservation compared to mammals. This last trait is of an 
advantage in our particular case; previous work from our lab identified Fbp1 as a 
response element of the DNA and protein damaging treatment of methyl methane- 
sulfonate MMS. A wide screen of transcriptional shifts following MMS treatment 
identified Fbp1 as one of the genes whose expression is induced within an hour of 
exposure to low doses of MMS.  
Originally Fbp1 is subject to glucose repression in yeast, hence it is completely 
repressed in glucose replenished conditions. Nevertheless, MMS induces the 
expression of Fbp1 in glucose rich media. The deletion of Fbp1 uncovered 
functional/phenotypic relevance for post-MMS Fbp1 induction. Fbp1-deficient (fbp1∆) 
cells exhibit less sensitivity to low doses of MMS. FBP1-deletion also abolished 
MMS-induced ROS accumulation. Similarly, FBP1-deficient cells exhibited less ROS 
induction upon chronological aging compared to wild-type cells of the same strains. 
This additional phenotype points out to a potential role of FBP1 in mediating 
genotoxicity. The aforementioned additional role can either stem from the enzymatic 
activity itself (e.g.: a result of changed glucose metabolism in absence of FBP1, or 
other metabolic products) or it can be due to an additional non-catalytic interaction of 
the protein. To address the origin of this functional and phenotypic duality of FBP1, a 
separation of the catalytic function from any other potential independent functions of 
the protein is necessary. This can be achieved by substituting functionally and 
structurally relevant residues, hence giving rise to analogues with reduced or 
completely annulled catalytic activity. Other aspects that can be altered via 
mutagenizing FBP1 are its subcellular localisation and its susceptibility to 
ubiquitination and subsequent degradation. The nuclear sub localization of the 
enzyme is of great interest due to reports on its non-catalytic function in the nuclei of 
human cancerous cells. In the nucleus, FBP1 interacts with Hif1a and prevents it 
from excreting its oncogenic transcriptional program. Manipulating the nuclear sub-
localization of the enzyme in yeast can uncover any possible specific nuclear 
functions in yeast, especially in the context of the dual phenotype discussed above.  
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The work on yeast is aimed at understanding the roles of FBP1 in yeast as a system 
per se, as well as enriching our perspective for exploring the regulation and effects of 
the enzyme in cancerous cells.  
To approach the issue in cancerous cells, I took on establishing and characterising 
models of FBP1 over-expressions and deletions in two breast cancer cell lines. My 
choice fell on breast cancer due to the heterogeneity of these tumours regarding 
FBP1 expression. Mainly, breast cancers fall into two broad categories; ductal and 
basal-like breast cancers. Tumours of the former type are primary tumours, epithelial 
in their morphology, hormone-dependent in their growth and are predominantly 
curable with high 5-year survival rates and generally good prognoses. In contrast, 
BLBCs are highly aggressive, metastatic tumours with mesenchymal morphology, 
hormone-independent, and have much worse prognosis. Among these tumours are 
the so-called triple negative breast cancers that lack the expression of Her2 
receptors, the epithelial marker E-cadherin, and the estrogen receptor. These are 
clinically designated as particularly critical, and they always lack FBP1 expression. 
Primary ductal breast tumours, including treated and regressed ones, are prone to 
relapse and further gain of aggressiveness that results from an epithelial-to-
mesenchymal transition EMT program, which confers further aggressiveness and the 
capability of metastasising. As already mentioned, FBP1 has a critical implication in 
this dynamic process. This makes breast cancer cells an ideal model to understand 
the impact of FBP1 on cancers in general, since they offer both contexts of FBP1 
absence or presence. 
 
   
II-Material and Methods 
 
“What I cannot create, I do not understand”. Richard Feynman 
 
II-I Instruments and equipment 
 
Yeast Culture: 
Shaking incubator: GFL3031 GFL, Burgwedel 
Agar plates incubator: Unitherm150 Uniequip, Martinsried 
CyBi® Well 96-channel simultaneous pipettor. 
Software: Opal Control CyBi –Well, Jena 
Cell Culture:   
CO2 incubator: NuAire Autoflow NU5510E NuAire, Minnesota 
Centrifuge: Eppendorf 5702 Eppendorf AG, Hamburg 
Water bath: GFL 1083 GFL, Burgwedel 
Microscope: Nikon Eclipse  Nikon, Düsseldorf 
Gel electrophoresis and immunoblotting:   
Gel electrophoresis set:  HoeferTM SE 260                              Amersham,  Little 
Chalfont 
Power supply for gel electrophoresis: EnduroTM Labnet Int, Edison 
Transfer device: BlueFlash-L  SERVA Electrophoresis, 
Heidelberg 
Power supply for transfer: PowerStation 200 Labnet Int, Edison NJ 
Analogue tube roller: Stuart SRT6 Stuart equipment 
Stone, Staffordshire 
Western Blot camera:  
LAS3000  imager: CCD camera and intelligent dark box. Software: LAS300 Image 
Reader FujiFilm, Minato (Tokio) 
Bellydancer Mixer/Shaker Stovall Life Sciences 
Greensboro, NC 
Native protein extraction: Bead mill MM300 Retsch®, Haan 
Cloning PCR and nucleic acid gel electrophoresis: 
RT-qPCR: qTower Analytik Jena, Jena 
Thermocycler: Eppendorf Eppendorf, Hamburg 
DNA/RNA Electrophoresis chamber: SubCell® GT Bio-Rad, Hercules CA 
Analysis instruments and devices:   
Plate reader: Tecan Infinite F200 pro Tecan, Männedorf 
Flow cytometer: FACS Guava easyCyte HT Merck Millipore, Darmstadt 
Bionas® 2500 analysing system Bionas, Rostock 
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Lab essentials:  
Eppendorf Research® Pipettes: 10, 20, 200, 1000 µl Eppendorf, Hamburg 
Vortex Genie2®  Scientific Industries Inc TM,
 Bohemia NY 
Thermomixer Comfort  Eppendorf, Hamburg 
Pipette controller: PIPETBOYacu2 Integra Biosciences, Zizers 
Mini centrifuge (Spin down device) Labnet Int, Edison NJ 
Automated dispensing systems: 
MultidropTM Combi Thermo Fisher Scientific 
 Weltham, MA 
VIAFLO® II Electronic pipettes Thermo Fisher Scientific 
VIAFLO Assist pipetting platform Thermo Fisher Scientific 
 
II-II Material 
Yeast Culture 
Utilized yeast strains 
All yeast strains were used in their haploidic form. The BY4741 strain is derived from 
S288-C with a quadruple deletion of popular selectable markers. The wild-type WT  
and Fbp1-deletion ∆fbp1 of this strain were harnessed for the mutational analysis of 
FBP1 described in this thesis.  
Table 1: Parental and transformed yeast strains with a BY4741 background. 
 
 Genotype Plasmid Source 
Parental Strains 
BY4741 wt MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 - EUROSCARF yeast collection 
BY4741 ∆fbp1 MATa his3Δ1, leu2Δ0, met15Δ0, 
ura3Δ0; fbp1::KanMX4 - EUROSCARF yeast collection 
    
Transformed strains 
BY4741 wt 
+ vector 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 (empty) This work 
BY4741 wt 
+ Fbp1 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 This work 
BY4741 wt 
+ Fbp1 P1A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 
P1A 
This work 
BY4741 wt 
+ Fbp1 N75A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 
N75A 
This work 
BY4741 wt 
+ Fbp1 D79A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 
D79A 
This work 
BY4741 wt 
+Fbp1 E109A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 
E109A 
This work 
BY4741 wt 
+Fbp1 D131A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 
D131A 
This work 
BY4741 wt 
+Fbp1 S133A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 
S133A 
This work 
BY4741 wt MATa his3Δ1; leu2Δ0; met15Δ0; pRS426 Fbp1 This work 
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+Fbp1 F194A ura3Δ0 F194A 
BY4741 wt 
+Fbp1H265A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 This work 
BY4741 wt 
+Fbp1H324A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
pRS426 Fbp1 This work 
    
BY4741 ∆fbp1 
+ vector 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 (empty) This work 
BY4741 ∆fbp1 
+ Fbp1 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 This work 
BY4741 ∆fbp1 
+ Fbp1 P1A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 
P1A 
This work 
BY4741 ∆fbp1 
+ Fbp1 N75A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 
N75A 
This work 
BY4741 ∆fbp1 
+ Fbp1 D79A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 
D79A 
This work 
BY4741 ∆fbp1 
+Fbp1 E109A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 
E109A 
This work 
BY4741 ∆fbp1 
+Fbp1 D131A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 
D131A 
This work 
BY4741 ∆fbp1 
+Fbp1 S133A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 
S133A 
This work 
 
BY4741 ∆fbp1 
+Fbp1 F194A 
 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
 
pRS426 Fbp1 
F194A 
 
This work 
BY4741 ∆fbp1 
+Fbp1 D131A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 This work 
BY4741 ∆fbp1 
+Fbp1H265A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 This work 
BY4741 ∆fbp1 
+Fbp1H324A 
MATa his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; fbp1::KanMX4 
pRS426 Fbp1 This work 
 
The FF18984 strain is highly resistant to DNA damage and genotoxic treatment, it 
contains deactivating knock-ins of 4 selectable markers. It was used in this work to 
assess long-term oxidative stress upon MMS exposure.   
Table 2: Parental and transformed yeast strains with FF18984 background. 
 Genotype Plasmid Source 
Parental Strains 
FF18984 wt MATa his7-1; leu2-3,112; lys2-1; 
ura3-52 - Provided by Prof. Dr. R. Walmsley  
Manchester, UK 
FF18984 ∆fbp1 MATa his7-1; leu2-3,112; lys2-1; 
ura3-52; fbp1::KanMX4 - Dissertation  Dr. A. Kitanovic 
    
Transformed strains 
FF18984 wt + 
GFP 
MATa his7-1; leu2-3,112; lys2-1; 
ura3-52 
pGenActGFP This work 
FF18984 wt +  
Fbp1 
MATa his7-1; leu2-3,112; lys2-1; 
ura3-52 
pGenAct Fbp1  This work 
FF18984 wt+ 
Grx1-roGFP2 
MATa his7-1; leu2-3,112; lys2-1; 
ura3-52 
p415TEF cyto 
Grx1-roGFP2 
This work 
    
FF18984∆fbp1+ MATa his7-1; leu2-3,112; lys2-1; pGenActGFP This work 
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GFP ura3-52; fbp1::KanMX4 
FF18984∆fbp1+ 
Fbp1 
MATa his7-1; leu2-3,112; lys2-1; 
ura3-52; fbp1::KanMX4 
pGenAct Fbp1  This work 
FF18984∆fbp1+ 
Fbp1-GFP 
MATa his7-1; leu2-3,112; lys2-1; 
ura3-52; fbp1::KanMX4 
pGenAct  
Fbp1-GFP  
This work 
FF18984∆fbp1+ 
Grx1-roGFP2 
MATa his7-1; leu2-3,112; lys2-1; 
ura3-52; fbp1::KanMX4 
p415TEF cyto 
Grx1-roGFP2 
This work 
 
 
Yeast Plasmids 
The over-expression vector of wild-type Fbp1 was established using the 
commercially available pRS426 plasmid with ura3 selection marker and constitutive 
GPD promoter. Wild type yeast Fbp1 was cloned into this over-expression vector by 
Dr. Ana Kitanovic as part of her PhD work.  
 
 
 
pRS426-GPD empty vector.  
 
The plasmids containing mutated cassettes of Fbp1 were established using PCR 
site-directed mutagenesis. The following table includes all the yeast plasmids used in 
this work.  
Table 3: yeast ectopic expression plasmids 
 
Plasmid Cloned Gene Promoter Selection Source 
pRS426-GPD 
(empty) 
- GPD Ura3 Dr. T.Munder, 
Jena,Germany 
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LB bacteria culture medium 
Yeast extract 5g/l 
NaCl 10g/l 
Tryptone/peptone 10g/l 
For plates: Agar 10g/l 
  
Yeast culture media 
General YPD medium  
Ready YPD broth (Sigma-aldrich) 
50 g for 1L.  
For plates: 20 g/l agar.  
Synthetic drop-out (SD) media 
pRS426-GPD 
Fbp1 (wt) 
Fbp1 GPD Ura3 Dissertation 
Dr. A.Kitanovic 
pRS426-GPD 
Fbp1 P1A 
Fbp1 P1A GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1 N75A 
Fbp1 N75A 
 
GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1 D79A 
 
Fbp1 D79A 
 
GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1 E109A 
Fbp1 E109A 
 
GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1 D131A 
Fbp1 D131A GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1 S133A 
 
Fbp1 S133A 
 
GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1 F194A 
Fbp1 F194A 
 
GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1H265A 
Fbp1H265A GPD Ura3 Diploma thesis 
J. Holzwarth 
pRS426-GPD 
Fbp1H324A 
Fbp1H324A 
 
GPD Ura3 Diploma thesis 
J. Holzwarth 
     
pGenAct-GFP GFP Actin Ura3 Prof. R.Walmsley, 
Manchester, UK 
pGenAct-Fbp1 Fbp1 Actin Ura3 Dissertation 
Dr. A. Kitanovic 
pGenAct-
Fbp1-GFP 
Fbp1-GFP Actin Ura3 Dissertation 
Dr. A. Kitanovic 
     
p415TEF cyto 
Grx1-roGFP2 
Grx1-roGFP2 TEF1 Leu2 Dr. T. Dick 
DKFZ, Heidelberg 
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Yeast nitrogen base YNB without amino acids (Sigma-Aldrich®) 6.7 g/l 
D-Glucose (CarlRoth®) 20 g/l 
L-Lysine 100 mg/l 
L-Leucin 100 mg/l 
L-Histidine 100 mg/l 
Uracil 20 mg/l 
For plates: 20 g/l agar 
Uracil or Leucin are eliminated from this formulation to yield SD-Ura or SD-Leu 
respectively.  
Synthetic drop-out ethanol glycerol SDEG (non-fermentable) medium 
Yeast nitrogen base YNB without amino acids (Sigma-Aldrich®) 6.7 g/l 
Ethanol 20% (v/v) 
Glycerol 20% (v/v) 
L-Lysine 100 mg/l 
L-Leucin 100 mg/l 
L-Histidine 100 mg/l 
Uracil 20 mg/l 
For plates: 20 g/l agar 
Uracil is eliminated from this formulation to yield SDEG-Ura.  
 
Cell culture 
Cell lines  
Breast cancer cell lines representing luminal MCF-7 and basal-like MDA-MB-231 
breast cancers were used.  
Table 4: parental cell lines  
 MCF-7 ATCC® MDA-MB-231 ATCC® 
Tissue of origin Mammary gland  Mammary gland 
Disease adenocarcinoma adenocarcinoma 
Receptor expression/ 
Genotype 
Estrogen receptor,  
E-Cadherin, Her-2 
Triple-negative, 
EGF and TGF-α Receptors 
FBP1 expression + - 
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Table 5: Full list of genetically altered cell-lines with different Fbp1 expression 
used in this work 
 Plasmid(s) Fbp1 Expression Selection Source 
Parental cell lines: 
MCF-7 - Endogenous - ATCC® 
MDA-MB231 - None - ATCC® 
Stable Knock-out cell line 
MCF7-Fbp1∆/∆ -Fbp1 double nickase 
-Fbp1 HDR 
Silenced (Gene 
disruption) 
Puromycin This work 
Stable Over-expressions 
MCF-7 
Vector (empty) 
pcDNA3.1(-)(empty) Only endogenous 
 
G418 This work 
MCF-7 oeFBP1 pcDNA3.1(-)Fbp1 Endogenous& 
Over-expression 
G418 This work 
MCF-7 oeFBP1 
N65A 
pcDNA3.1(-)Fbp1 N65A Endogenous& 
oeFBP1 N65A 
G418 This work 
MCF-7 
oeFBP1 P6A 
pcDNA3.1(-)Fbp1 
P6A 
Endogenous& 
FBP1 P6A 
G418 This work 
MCF7 Fbp1∆/∆ 
oe yeastFBP1 
pcDNA3.1(-)Fbp1 
yeastFBP1 
Endogenous& 
yeastFBP1 
G418 This work 
MCF7-Fbp1∆/∆ 
Vector (empty) 
pcDNA3.1(-)(empty) none   
MCF7-Fbp1∆/∆ 
oeFBP1 
pcDNA3.1(-)Fbp1 Over-expression G418 This work 
MCF7-Fbp1∆/∆ 
oeFBP1 N65A 
pcDNA3.1(-)Fbp1 N65A FBP1 N65A G418 This work 
MCF-7 Fbp1∆/∆ 
oeFBP1 P6A 
pcDNA3.1(-)Fbp1 
P6A 
FBP1 P6A G418 This work 
MCF7 Fbp1∆/∆ 
oe yeastFBP1 
pcDNA3.1(-)Fbp1 
yeastFBP1 
yeastFBP1 G418 This work 
     
MDA-MB231 
Vector (empty) 
pcDNA3.1(-)(empty) none 
 
G418 This work 
MDA-MB231 
oeFbp1 
pcDNA3.1(-)Fbp1 Over-expression G418 This work 
MDA-MB231 
oeFbp1N65A 
pcDNA3.1(-)Fbp1 N65A FBP1 N65A G418 This work 
MDA-MB231 
oeFBP1 P6A 
pcDNA3.1(-)Fbp1 
P6A 
FBP1 P6A G418 This work 
MDA-MB231 
oe yeastFBP1 
pcDNA3.1(-)Fbp1 
yeastFBP1 
yeastFBP1 G418 This work 
MDA-MB231 
oe yeastFBP1 
pcDNA3.1(-)Fbp1 
yeastFBP1 P1A 
yeastFBP1 P1A G418 This work 
 
To establish the over-expression of human and yeast Fbp1 in cancer cell lines, new 
vectors had to be constructed, desired mutations were then introduced into the 
vectors containing human or yeast Fbp1 using PCR site-directed mutagenesis. The 
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commercially available pcDNA3.1(-) vector with the mammalian-constitutive CMV 
promoter and Geneticin (G418) selectable marker was used to construct the required 
plasmids for Fbp1 expression in human cancer cells.  
 
Table 6: List of the mammalian plasmids used in this work to ectopically express 
different forms of Fbp1 into cancer cell lines: 
 
 
Plasmid 
 
 
Cloned Gene 
 
 
Promoter 
 
 
Selection 
 
 
Source 
pcDNA3.1(-) - CMV G418 This work 
pcDNA3.1(-) 
Fbp1 
Fbp1 CMV G418 This work 
pcDNA3.1(-) 
Fbp1 P6A 
Fbp1 P6A CMV G418 This work 
pcDNA3.1(-) 
Fbp1 N65A 
Fbp1 N65A CMV G418 This work 
pcDNA3.1(-) 
yeast Fbp1 
yeast Fbp1 CMV G418 This work 
pcDNA3.1(-) 
yeastFbp1 P1A 
Yeast Fbp1 P1A CMV G418 This work 
 
The stable knock-out of fbp1 in MCF-7 was established using a combination of fbp1-
specific CRISPR Cas-9 double-nickase and homology directed repair HDR plasmids. 
The plasmid pair was purchased from SantaCruz Biotechnology® catalog number: 
sc420299-NIC 
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Table 7: Human CRISPR-Cas9 deletion constructs:  
Plasmid Expressed Gene Promoter Selection Source 
FBPase double-
nickase  
Cas-9 (D10A) 
GFP 
U6 - SCBT® 
FBPase HDR Puromycin 
RFP 
EF-1a Puromycin SCBT® 
 
The pairs of cloning primers used for cloning Fbp1 into pcDNA3.1(-):  
Human Fbp1:  
Forward: tttttgaattcATGGCTGACCAGGCGCC 
Reverse: tttttaagctttcactgggcagagtgcttctc 
Yeast Fbp1:  
Forward: tttttctcgagatgccaactctagtaaatg 
Reverse: tttttaagcttctactgtgacttgccaat 
Yeast Fbp1 P1A: 
Forward: tttttctcgagATGGCAACTCTAGTAAATGGACC 
Reverse: TTTTTAAGCTTctactgtgacttgccaatatgg 
 
The expression plasmids of the mutated forms of human Fbp1 were constructed by 
mutagenizing the pre-cloned pcDNA3.1(-)Fbp1 using the following site-directed 
mutagenesis primer pairs:  
Fbp1 P6A:  
Forward: gctgaccaggcggccttcgacacggac 
Reverse: gtccgtgtcgaaggccgcctggtcagc 
 
Fbp1 N65A:  
Forward: cattgctggttctaccgccgtgacaggtgatcaag 
Reverse: cttgatcacctgtcacggcggtagaaccagcaatg 
Table 8: Real-time quantitative PCR primers 
Gene Primers 
Human fbp1 For: GCCCCAATGGAAAGCTGAGA Rev: GTCTAACACGGCCTCCTTCC 
GAGCCCCAATGGAAAGCTGA Rev: ATGACGTCTAACACGGCCTC 
Yeast fbp1 For: CAAGCCTTTCTCGGCTAGGT Rev: AGTTTTCCGTTGGGGCTCTT 
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CENPE For: AAATTTAAAGGCGGGGCGG Rev: TGGGCAGTTTCTCCAAGTGA 
UCH-L1 For: GGAAGGCCAATGTCGGGTAG Rev: GCAGGGTGTCCTCTGAACTG 
TGFβ-R3 For: GTCGGCCTGATGGGGGTA Rev: GAATCGCGCAGGGAAAGTG 
e-cadherin For: CAGTTCAGACTCCAGCCCG Rev: CTGGCAGAGCCAAGAGGAG 
TRIM-28 For: GGATGTACCAGGGGAGGAGT Rev: TACACGCTCACATTTCCGCT 
MAGE-A3/6 For: TCGGTGAGGAGGCAAGGTTC Rev: CAGTGCTGACTCCTCTGCTC 
MAGE-C2 For: ACGGCCATCTTGGGAATCTG Rev: TATGGTGGGAGGTCCCTCAG 
Glutaminase For: CTTTCCCCAAGGACAGGTGG Rev: CGGTTTGATTTTCCTTCCCGT 
HIST2H2AC For: GGCTCGGGACAACAAGAAGA Rev: AGAACGGCCTGGATGTTAGG 
FAM38 For: TTCCAGACCGTCAAGCACAA Rev: GAGCACACAAACGAACACCC 
AURKA For: GGAAGACTTGGGTCCTTGGG Rev: GAACCGACAGGGGACTTGAC 
β-Actin For:CATTCCAAATATGAGATGCGTTCG Rev: GCTATCACCTCCCCTGTGTG 
Vinculin For: CAGTCAGACCCTTACTCAGTG Rev: CAGCCTCATCGAAGGTAAGGA 
RPL-30 For: GGTGTCCATCACTACAGTGG  Rev: GTCAGAGTCACCTGGATCAATG 
 
Cell culture consumables 
• Cell culture media:  
As a standard medium, full Dulbecco modified Eagle medium DMEM 
(Gibco®, Thermo Fisher Scientific) was used with 10% (v/v) FCS (Gibco®, 
Thermo Fisher Scientific) in addition to penicillin streptomycin (final 
concentration= 50U/ml) (Gibco®, ThermoFischer  Scientific).  
• Cell culture well plates:  
CELLSTAR® 6 well cell culture plate (Greiner Bio-one, Kremsmünster) 
CELLSTAR® 12 well cell culture plate (Greiner Bio-one, Kremsmünster) 
CELLSTAR® 96 well cell culture plate (Greiner Bio-one, Kremsmünster) 
• Cell culture flasks:  
Cellstar® T25 and T75 cell culture flasks with filter caps. (Greiner Bio-one, 
Kremsmünster) 
 
 
Reagents and buffers: 
- DNA gel electrophoresis: 
• Agarose gel: 
1% (w/v) agarose, 1:10000 ethidium bromide (Stock solution: 1mg/ml), 
complete volume to 100 ml TAE or TBE buffer.    
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• TAE Buffer (1X):  
40 mM Tris (pH 7.6)  20 mM acetic acid  1 mM EDTA 
• TBE Buffer: 
89 mM Tris (pH 7.6) 89 mM boric acid, 2 mM EDTA 
• DNA loading dye: 
6X Loading Dye Solution (Fermentas® LifeSciences, Thermo Fisher Scientific) 
(10 mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03 % xylene cyanol FF, 
60 % glycerol and 60 mM EDTA.) 
• Protein marker:  
Lambda DNA/PstI Marker, 24 (Fermentas® LifeSciences, Thermo Fisher 
Scientific) 
 
- Western-blot 
• Polyacrylamide gels for SDS-PAGE: 
 15mL of 12% 
resolving gel 
 5mL of 5% stacking gel 
H2O 5.9 3.4 
30 % acrylamide mix 5 0.83 
1.5 M Tris‐HCl pH8.8 3.8 - 
1.0 M Tris‐HCl pH6.8 - 0.63 
10 % ammonium persulfate 0.15 0.05 
TEMED 0.006 0.005 
 
• Anode buffer: 
• 25 mMTris;40 mM6‐amino‐n‐capronic acid;10 % methanol; pH 9.4 
• Cathode Buffer: 
• 25 mMTris; 40 mM6-‐amino‐capronic acid; 10% methanol; pH 9.4 
• TBS‐Tween: 
8.0 g/L NaCl; 0.2 g/L KCl; 3.0 g/L Tris;pH 7.4; 0.1% Tween. 
• Protein Loading dye: 
PLB‐10 mM Tris‐HCl; 20% glycerol; 200 mM β‐mercaptoethanol and 0.2%(v/v) 
Bromphenol-blue 
• SDS-PAGE running buffer: 
250 mM glycin and 25 mM Tris ‐HCl. 
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II-III Methods    
Molecular cloning and construction of plasmids  
To ectopically express Fbp1 (with its different homologues and mutations) in cell 
lines, new plasmids had to be constructed with Fbp1 variants expressed under a 
mammalian promoter. For this purpose I started with the commercially available 
pcDNA3.1(-) vector (see material section).  
A restriction cloning strategy was followed with restriction sites introduced on 5`end 
of each primer so that to flank the resulting Fbp1 PCR product. The restriction sites 
were chosen as to avoid cutting the insert and to have matching sites in the multiple 
cloning region of the pcDNA3.1 vector.  
The following steps were implemented to construct the plasmids:  
- PCR amplification of the product human or yeast Fbp1 (Using Phusion 
polymerase, NEB®).  
- Column purification of the PCR product ( 
- Overnight restriction digest of the purified PCR product and the plasmid using 
matching restriction enzymes at 37° followed by a 20 min inactivation step at 
80°.  
- Gel purification of the digested vector and PCR product (insert) ().  
- Overnight ligation of the vector and insert at molar ration of 1:3 (vector::insert) 
(T4 DNA ligase, NEB®). 
- Transformation of the resulting ligation product into E.coli.  
- Following transformation and selection, Mini-preps were made of picked 
colonies and these were sent for sequencing (Eurofins Genomics, Ebersberg).  
PCR site-directed mutagenesis 
To prepare the expression vectors of mutated human Fbp1 a site-directed PCR 
mutagenesis approach was harnessed using the Q5® Site-directed mutagenesis kit 
from NEB. The method depends upon the amplification of the entire plasmid using 
primers harbouring the desired single or double mismatch mutation, once amplified 
the mutation becomes integral to the Fbp1 cassette in the resulting amplified vector. 
The template is then degraded based on its unique DNA methylation pattern (the 
template is a plasmid prepared in bacteria, and therefore has a unique E.coli-
associated methylation pattern compared to the unmodified PCR product) using the 
methylate-DNA specific DNPI restriction enzyme. Simultaneously, the yielded PCR 
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product is phosphorylated and ligated by enzymes that exist in the same mixture as 
DnpI.  
A following over-view of the site-directed mutagenesis protocol provided with the 
utilized Q5® Site-Directed Mutagenesis NEB® kit:  
- Mutagenesis Primers with the desired point mutations were designed using 
the NEBase Changer online tool from NEB®.  
- PCR Amplification of the plasmid using Q5 polymerase (following the protocol 
provided with the kit).  
- Digestion of the template plasmid, phosphorylation and ligation of the mutated 
product DNA using the KLD (kinase, ligase and DpnI treatment (5 minute 
incubation at room temperature) enzyme mix and buffer. 
- Transformation of E.coli with the resulting mutated plasmid.  
Preparation of chemically competent DH5αTM E.coli cells (Thermo Fischer 
Scientific)  
- Bacteria were cultured in 2 ml LB over-night at 37°c.  
- 1 ml of the over-night culture were then diluted up to 150 ml of LB medium, the 
culture was subsequently grown up to an O.D600=0.6 (about 2.5-3 horus).  
- Subsequently the cultured bacteria were pelleted and re-suspended in 15 ml 
TSB buffer (1*LB, 5% DMSO, 10 mM MgCl2, MgSO4, 10 mM PEG 4000).  
- The TBS bacterial suspension was kept on ice for 10 minutes. 
- The suspension was divided into individual 100 µl aliquots that were kept on 
dry ice and subsequently preserved at -80°c.  
 
Transformation of chemically competent E.coli 
- The following transformation mixture is prepared in an Eppendorf tube for 
each transformation in addition to one mock reaction (treated exactly similarly 
to the transformation, but excluding the plasmid DNA):  
o 20 µl KCM buffer (0.5 M KCl, 0.15 M CaCl2 and 0.25 M MgCl2). 
o 1 ng of a previously prepared plasmid DNA, or 10 µl (25 ng) of a ligation 
mixture for newly constructed plasmids.  
o Fill up to 100 µl with sterile water.  
- An aliquot of chemically competent E.Coli was thawed on ice, and added onto 
the above mentioned transformation mixture.  
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- The resulting suspension of bacteria in the transformation mixture was 
incubated for 40 minutes on ice.  
- Competent cells were then heat-shocked for precisely 45°at 42°c in a 
preheated water bath.  
- The heat-shock was terminated by promptly placing the cells on ice.  
- Subsequently cells were pelleted and plated on LB-agar containing 100 µg/ml 
Ampicillin.  
- After over-night incubation, growing colonies were inoculated in 3 ml liquid LB 
with Ampicillin. 
- On the following day, the resulting liquid colonies were harnessed to make 
mini plasmid preparations.  
- In the case of newly cloned plasmids, samples were sent for sequencing to 
confirm that the correct construct had been obtained. 
 
Transformation of S.cerevisiae using the lithium acetate method   
Chemical genetic transformation of yeast was used to introduce expression vectors 
containing the wild-type and various mutated forms of Fbp1 and thus have them 
ectopically expressed under constitutive GPD or Actin promoter.  For this I used the 
following modified protocol from the lithium acetate methods first introduced by Gietz 
and Woods (1995)[77].  
I) Preparation of chemically competent yeast  
- A single colony is inoculated in 3 ml general YPD medium and incubated for 
24 h at 30°. 
- 4 µl of the above mentioned pre-culture were inoculated in 50 ml YPD and 
incubated for 16 h (≈10 generations). 
- Over-night culture was pelleted at 1000 xg for 5 minutes in 50 ml falcon tube.  
- Cells were washed in 20 ml sterile water, pelleted and re-suspended in 1 ml 
sterile water, transferred into an Eppendorf tube and pelleted again.  
- The cell pellet was re-suspended in a 0.1 M lithium acetate solution (500 µl for 
each 100 µl pellet). 
- To reach chemical competency, cells were incubated in the lithium acetate 
suspension for 20 minutes at 30°c.  
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II) Transformation 
- For each transformation and one additional mock (treated precisely like the 
transformations, but lacking plasmid DNA): denature 5 µl of the carrier DNA 
(Herring sperm DNA, Sigma-Aldrich®) by boiling for 10 minutes in a heating 
block and then moving the tubes promptly onto ice.  
- For each transformation: 0.5 to 1 µg of plasmid DNA were taken and mixed 
with the carrier DNA.  
- 100 µl of competent cells (prepared in one liter) were added to the carrier & 
plasmid DNA mixture followed by 20 min incubation at 30°c.  
- 600 µl of LiAc (0.1 M) and PEG4000 (40 %) mixture were added to the cells. 
After mixing very well the suspension was incubated for 20 minutes at 30°c. 
-  71 µl of sterile DMSO were added to each transformation (final concentration 
10 %).  
- Cell suspensions were heat-shocked for 15 minutes at 42°c (in an accurately 
preheated water bath). 
- Following 15 minutes the heat-shock was terminated by promptly placing the 
cell suspensions on ice. 
-  After aspirating the supernatant, cells were resuspended in 800 µl YPD 
medium and moved into culture tubes containing 800 µl of YPD (final culture 
volume 1.6 ml). 
- Cells were shaken for 3 h at 30°c.  
- After being pelleted and washed once in sterile PBS, cells were pelleted again, 
re-suspended in 50 µl SD-Ura and plated on SD-Ura agar plates.  
- Following 2 to 3 days of incubation, transformation plates were inspected for 
emerging colonies. Colonies were then picked and spread on new agar plates 
and successful transformation was phenotypically confirmed.   
 
Transfection of cell lines and establishing stable over-expressions and 
deletions 
I resorted to lipid-based transfection using LipofectaminTM3000 (Thermo Fisher®, 
Waltham MA) for introducing the desired expression vectors into cancer cell lines. 
The transfections were performed using the protocols provided with the transfection 
reagents. The following steps were adhered to:  
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- After trypsinisation cells were counted and seeded in a 6 well-plate at a 
density of 300.000-500.000 cells per well.  
- Following 24 to 48 hours incubation and after reaching a confluency of 70% to 
90%, cells were transfected.  
- The transfection mixture was prepared by adding pre-mixed 2.5 µg plasmid 
DNA with 5 µl p3000 reagent in 125 µl Opti-MEM to pre-mixed 7.5 µl in 125 µl 
Opti-MEM, for each transformation 
- The trnasfection mixtures were mixed by inverting the containing tubes and 
then incubated for 15 minutes at room temperature.  
- 250 µl transfection mixture were pipetted onto each well, slowly and drop-wise.  
- The 6 well-plates containing the newly transfected cells were subsequently 
shaken gently.  
- Following 24 hours of incubation, medium was replaced and cells were further 
incubated for 24 more hours.  
 
I) Establishing cell lineages with stable over-expression 
- After giving cells 24 hours of recovery from the transfection, cells were treated 
with medium containing G418 sulphate (900 µg/ml for MCF-7, 1200 µg/ml for 
MDA-MB231). 
- Medium with antibiotic was replaced once every 3 to 4 days.  
- Following 3 to 4 weeks of selection in 6 well plate format (control non-
transfected cells completely wiped out), transfected cells were trypsinised and 
transferred into a T25 cell culture flask.  
- The G418 selection pressure was maintained as part of the cell culture 
medium in which the transfected cells were cultivated.    
- Over-expression of Fbp1 was then verified on the mRNA and protein levels, 
using qPCR and immunoblotting, respectively.  
-  
II) Establishing the stable CRISPR-Cas9 deletion of Fbp1 in MCF-7  
- To achieve the knock-out of fbp1 in MCF-7, cells were double transfected with 
a CRISPR-Cas9 Double Nickase (Cas9 D10A mutant) plasmid containing two 
gRNAs directed to the opposite strands of the fbp1 gene and a homology-
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directed repair plasmid containing the selectable Puromycin resistance marker 
flanked with sequences matching the disruption site indicated by the gRNAs.  
- 24 hours post-transfection, medium was replaced and cells were given 48 
hours for recovery and developing Puromycin resistance.  
- Subsequently cells were selected using 200 ng/ml Puromycin with medium 
containing the same concentration of Puromycin changed every 3 to 4 days.  
- 6 weeks following transfection, cells were trypsinised and transferred into a 
T25 cell culture flask, and Puromycin was withdrawn from the culture medium.  
- The successful deletion was verified on mRNA and Protein levels, and the 
resulting deletion cell lineage was continuously monitored to ensure the 
stability and irreversibility of the Fbp1 deletion.  
 
Yeast spot assays (drop-tests) 
i) Growth on non-fermentable carbon sources, drop test on SDEG medium 
Starting from Mid-Log phase cultures, cell suspensions with the following dilution 
factors were prepared via serial dilution (1:10). 
1:1; 1:10; 1:100; 1:1000; 1:10000; 1:100000. 
Subsequently, 4 μl of each cell suspension of the examined yeast strains were 
adjacently dropped onto SDEG-agar. Agar plates were incubated for 48 h at 30 °C 
and then imaged to assess the growth of the strains over-expressing either wild type 
or mutant versions of Fbp1p.  
ii) Sensitivity to MMS treatment 
Starting from over-night cultures, cell-suspensions OD was adjusted to 10, and these 
suspensions were serially diluted (1:5) to yield suspensions with the following OD600 
(10; 2; 0.4; 0.08; 0.0016; 0.00032). 4 μl of each suspension was then spotted onto 
freshly prepared SD-Ura plates containing varying concentrations of MMS (0.01% to 
0.0175%). 
The plates with 0.01% MMS, and those with 0.015% or 0.0175% MMS were 
incubated at 30 °C for 48 h and 72 h, respectively. 
iii) Drop-test Image-Quantification 
Spot-intensities from drop-tests were quantified using ImageJ, spot intensities from 
MMS plates were then normalized to those of the non-treated control, and values 
from mutants were normalized against the strain with wt Fbp1. 
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Continuous measurement of yeast growth in liquid medium 
Over-night cultures were first diluted to an OD600 of 0.2, and shaken for 3 hours. 
Subsequently cultures were transferred into 96 round-bottom well-plates, 200 μl per 
well. Of each used cell type, three wells were treated with 0.02% MMS, and three 
wells with 0.01% MMS while four wells were kept untreated. 
The 96 well plates were then incubated at 30°c inside the microplate reader (Tecan-
Ultra). OD600 of each well was measured every hour for 32 h, 15 min of shaking 
within the plate reader preceded each measurement. 
 
Protein extraction 
Depending on the application, protein extracts were either prepared in native or 
denaturing conditions. Enzymatic activity measurements require intact protein folding, 
and thus necessitate protein extraction in non-denaturing conditions. While SDS-
Page and immunoblotting are performed on denatured protein extracts. 
 
Denaturing protein extraction 
To extract total proteins from cells, 3*105 to 5*105 cells were seeded, following 24 to 
48 hours of incubation cells were subjected to the desired treatment or medium 
conditions and then lysed in 6 M urea buffer containing the following protease 
inhibitors: (NaF, PMSF, Pepstatin, Aprotenine and NaVO4). To lyse the cells, medium 
was aspirated, and 120 to 180 µl ice-cold 6 M Urea buffer were pipetted directly onto 
the cells. Subsequently, the cell culture plates were promptly placed on ice and then 
vortexed to ensure full homogenization in the Urea buffer. Afterwards, lysates were 
collected in Eppendorf tubes and then spun down at 13000 g for 15 minutes to get rid 
of the DNA. Lysates were subsequently stored at -20°C.  
 
Native (non-denaturing) protein extraction 
To preserve proteins folding and function, cells were mechanically lysed in mild non-
denaturing conditions.  Since the mechanical disruption of cells in a bead-mill set 
remains less efficient in completely breaking down cells and extracting their individual 
proteins, higher cell numbers were used to harness sufficient non-denatured protein 
for the enzymatic activity assays.  
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For this a one to 1.one and a half million cells were cultivated in cell-culture standard 
size Petri dishes and incubated with full DMEM (with G418 for cells harbouring 
plasmids) for 24 to 48 hours. Subsequently, cells were trypsinised, pelleted and lysed 
using the bead-mill according to the following protocol:  
- Pellets were resuspended in 1ml ice-cold PBS and transferred into Eppendorf 
tubes, centrifuged again and resuspended in 1 ml fresh ice-cold PBS.  
- 1 g of acid-washed glass-beads (Sigma-Aldrich) was added to the cell 
suspension.  
- Cells were then homogenised by shaking at a frequency of 30 Hertz using the 
bead-mill.  
- To avoid over-heating of the suspension due to rapid mixing and the resulting 
protein denaturation, homogenisation was performed in shaking/cooling 
rounds as follows: 
- 5 minutes shaking followed by 5 minutes on ice, repeated 3 times and followed 
by a last homogenisation round of continuous 10 minutes.  
- Finally the suspensions of beads and lysed cells were spun down at 16000*g 
for 15 minutes at 4°c and clear lysates were aspirated, moved into fresh 
Eppendorf tubes and stored at -20°c or immediately used for the enzymatic 
activity measurements. 
-  
Yeast nuclear/cytoplasmic protein extraction  
Cells from over-night culture in SD-Ura medium were pelleted at 1000x g. Afterwards 
pellets were re-suspended in 1 ml 0,8 M NaCl containing 0,2 mg Zymolase and 
incubated for 30 min at room temperature. The resulting spheroplasts were then spun 
down and re-suspended in 1 ml 10 mM Tris containing protease inhibitors. 
Subsequently ca. 100 μl glass beads were added and spheroplasted cells were 
crushed using the bead mill homogeniser MM300 (Retsch) at full speed for 10 min 
followed by 10 min on ice. This homogenization/cooling cycle was repeated three 
times and lysates were obtained. Nuclei were isolated from the rest of the lysates 
using differential centrifugation at 1000 x g for 5 min. The supernatant containing the 
cytosolic fraction of the lysate was isolated and stored at -20°C, and the yielded pellet 
with the nuclear fraction was resuspended in 0.5 ml 10 mM Tris then centrifuged at 
300 x g to remove the cell debris. The remaining supernatant after this step contains 
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the floating nuclei and was isolated and stored at -20°C. Both nuclear and cytosolic 
fractions were analyzed using SDS-Page followed by western blotting to investigate 
the presence of the various mutated forms of Fbp1p in transformed strains containing 
their respective overexpression vectors. 
 
Determining total protein concentrations 
Total protein concentrations in the lysates were determined using Bradford reaction. 
10 µl of each lysates were mixed with 990 µl of Bradford reagent (Sigma-Aldrich) in 
Eppendorf tubes. Samples were then mixed and incubated for 5 minutes in the dark. 
Subsequently 3x300 µl of each sample were transferred into 96 well-plates and 
measured using the Tecan Ultra (Tecan, Germany) reader at 595 nm.  
 
SDS-PAGE and immunoblotting 
Proteins in denatured lysates were resolved on 10% polyacrylamide gel (SDS-PAGE) 
as described in (Laemmli, 1970)[78]. Afterwards, resolved proteins were blotted 
(transferred) from the resolving SDS-PAGE gel onto a PVDF membrane.  Semi-dry 
protein transfer was used with anode and cathode buffer prepared as detailed in the 
above material section.  
Subsequently, membranes were stained with ponceau S (5% ponceau S) and then 
washed in TBS-tween 1% (v/v) buffer and blocked in a 5% BSA solution in TBS-
tween buffer for 1 hour, and then incubated with 1:1000 solution of one of the used 
primary antibodies. After the primary anti-body incubation, membranes were washed 
3 times for 5 minutes each in TBS-tween 1 buffer and subsequently incubated in 
1:5000 HRP-fused anti rabbit or anti mouse secondary (IgG) anti-body solutions for 1 
hour. Finally, membranes were washed 3 x 5 minutes and developed in Western 
Lightning Plus-ECL (Perkin-Elmer, Germany). Signals were detected using the 
Fujifilm LAS-3000 imaging system and the AIDA software for image acquisition.  
 
Quantification of western-blot signals 
the intensities of the western-blot bands of target proteins were quantified using the 
Image-J histogram quantification tool. The intensity of the target protein signals was 
adjusted relative to the corresponding loading-control (beta-actin) bands.  
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Assessment of enzymatic activity in crude native protein extracts 
i) FBPase activity 
Total fructose 1,6 bis-phosphatase activity was measured using cytosolic protein 
extracts of over-night cultures of yeast cells as described by Skalecki et al. [79] The 
general principle of the assay depends on coupling FBPase catalysis to the formation 
of NADPH through the phospho-glucose isomerase PGI and glucose-6-phosphate 
dehydrogenase G6PD present in the reaction mix. Dephosphorylation of fructose 1,6 
bis-phosphate by Fbp1 yields Fructose 6 phosphate, which is then converted to 
glucose 6 phsophate by PGI. G6P is then oxidized by G6PDH with NADP+ getting 
reduced to NADPH. 
Thus the ratio of the yielded F6P molecules and the NADPH is 1:1.  
         
In practice, this measurement was performed in a 96 well plate format as follows: 
 3 x 10 µl of each native lysate to be tested were pipetted into 3 separate wells. 
Subsequently, the following components were mixed to constitute the full reaction 
mix: 
Reaction buffer: 75 µl 
PGI (5 U/µl): 0.15 µl (0.75U/reaction).  
G6PD: (0.7 U/µl): 1 µl (0.70U/reaction).  
NADP+ (5 mM): 15 µl (final conc.= 0.5 mM) 
Fructose1,6 bis-phosphasate (17mM): 1.5 mM (final conc.= 0.17 mM) 
After thoroughly mixing the abovementioned components for the required number of 
reactions, 140 µl of the resulting reaction mixture were pipetted on each well 
containing the pre-pipetted protein lysates. Plates were then shaken for 2 minutes 
and then the kinetic measurement of absorption of the yielded NADPH (λmax=340nm) 
was started. The FBPase activity was derived from the slope of the linear part of the 
increase in NADPH absorption over time, which reflected the reaction rates. The 
enzymatic activity was then calculated in mU/mg (total protein) using the following 
equation:    
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€ 
FBPase(mU /mg) = OD340
t 2 mU[ ] −OD340t1 mU[ ]( )*161
(t2 − t1)*Protein(mg)  
ii) G6PD activity 
The assessment of G6PD activity in crude native lysates depended on measuring the 
UV-absorption of the NADPH directly yielded by the reaction. The activity was 
measured in the presence of an excess amount of the substrate glucose-6-
phosphate, hence rendering the reaction rate a function of the availability of the 
enzyme only. G6PD oxidizes glucose-6phosphate with NADP+ as a cofactor yielding 
6-phospho-glucono-lactone and reduced NADPH with a maximal absorption at 
λmax=340nm.  
 
This measurement was performed in a 96 well plate format as follows:  
3x10 µl of each non-denatured lysated proteins to be tested were pipetted in 3 
separate wells.  
Subsequently, the following components were mixed to constitute the full reaction 
mix: 
Reaction buffer: 50 mM Tris-HCl buffer (pH=8.2), 100 mM KCl, 5 mM MgSO4. 
Glucose-6-phosphate G6P: working concentration 50 µM 
NADP+: working concentration: 0.8 mM 
After thoroughly mixing the abovementioned components for the required number of 
reactions, 140 µl of the resulting reaction mixture were pipetted on each well 
containing the pre-pipetted protein lysates. Plates were then shaken for 2 minutes 
and then the kinetic measurement of absorption of the yielded NADPH (λmax=340nm) 
was started. The relative G6PD activity was derived from the slope of the linear part 
of the increase in NADPH absorption over time, which reflected the reaction rates. 
 
FACS analysis  
i) Yeast 
Overnight liquid cultures were diluted to an OD600 of 0.1-0.2, and then grown into the 
log-phase (OD600 ≈0.4-0.6). Afterwards, cell suspensions were transferred into 96 
round-bottom well plates. Cells were treated in the well plates in triplets and by 
following the intended duration of the treatment. 
To quantify dead-cell fractions, propedium iodide was added to the medium (final 
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concentration 3 µg/ml). Following 5 minutes incubation in the dark, plates were 
shaken for 2 minutes and then acquired using the FACS Guava with an auto-
sampler. The percentage of dead cells was then determined by quantifying the PI-
positive cells.   
 
ii) Cell culture  
Fluorescence activated cell sorting FACS analysis was used to measure a variety of 
metabolic and viability markers in the cells. Cells were seeded in 12 well plates at a 
density of 50,000 cells/well in 1 ml full DMEM/well and incubated over-night. On the 
following day medium was aspirated, and cells were treated as indicated for each 
experiment). Following treatment, cells were incubated with the fluorescent probes 
(details and conditions for each fluorescent probe are listed below) then analysed 
using FACS Guava (Merck-Millipore, UK). All FACS acquisitions were automated and 
performed in a 96 well-plate setting.   
 
Measuring glucose uptake using fluorescently labelled 2-Deoxy-Glucose 
2-NBDG 
Akin to 2-deoxyglucose, 2-NBDG is taken up by cells and phosphorylated. The 
resulting 6-Phopsho-2-NBDG is sequestered in the cytosole and cannot 
undergo further glycolytic steps. Therefore, it accumulates in the cells and is 
used in low concentrations as an indicator of intracellular glucose uptake [80].    
Fluorescently labelled 2-deoxyglucose 2-NBDG was added to the cell culture 
medium at a concentration of 50 µM so that cells were treated with both 
indicated agents and the labelled 2-DG simultaneously. After 3 hours cells 
were washed once with PBS, trypsinized, pelleted (200x g, 3 minutes) and re-
suspended in DMEM without phenol red (colourless), round-bottom 96 well 
plate and analysed.  The 2-NBDG green fluorescence was then quantified 
(mean-value of the sample population) and plotted. 
 
Assessing ROS levels using dehydroethidium DHE 
Dehydroethedium DHE, is a RedOx probe that interacts to reactive oxygen 
species, including superoxide, forming fluorescence ethedium and other 
derivatives thereof that chelate the DNA and hence generate a stable red 
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fluorescence signal proportional to the amount of intracellular ROS [81]. 
Following the intended duration of treatment, cells were washed once with 
PBS, trypsinised, pelleted (200x g, 3 minutes) and re-suspended in full DMEM 
with 30 µg/ml dehydroethidium DHE (Biomol, Germany) and incubated for 15 
minutes. Subsequently cells were pelleted again, and resuspended in DMEM 
without phenol red (colourless), transferred into round-bottom 96 well plate 
and analysed. The DHE red fluorescence was then quantified (mean-value of 
the sample population) and plotted. 
 
Assessing mitochondrial mass using MitoTracker® Green 
MitoTracker® Green To compare assess the variations in mitochondrial mass 
between cells with different Fbp1-expression status. MitoTracker Green is a 
fluorescent dye that localises to the mitochondria independent of mitochondrial 
inner-membrane potential, making it suitable for assessing mitochondrial mass 
independent of mitochondrial function. For measuring mitochondrial mass, 
treated cells were washed once with PBS, trypsinized, pelleted (200x g, 3 
minutes) and re-suspended in DMEM without FCS with MitoTracker Green 
(2nM) (Thermo-Fischer Scientific, Weltham, MA) and incubated for 30 
minutes. Subsequently cells were pelleted again, and resuspended in DMEM 
without phenol red (colourless), transferred into round-bottom 96 a well plate 
and analysed. The mean values of green fluorescence of each population 
were calculated as an indicator of the mitochondrial mass was. 
Determining mitochondrial inner-membrane potential using JC-1 
JC-1 is a cyanine dye suitable for the fluorescent assessment of mitochondrial 
function by measuring the mitochondrial inner membrane potential. Healthy 
and active mitochondria maintain high levels of inner-membrane potential as a 
result of an active respiratory chain. The JC-1 dye concentrates on the inner-
side of the polarised mitochondrial membranes undergoing a fluorescent shift 
from green (free monomeric dye) to red (aggregated JC-1). Therefore, the 
ration of red/green fluorescence signals of JC-1 dye enables the assessment 
of the mitochondrial membrane polarisation and function[82].   
For measuring mitochondrial membrane potential with JC-1, treated cells were 
washed once with PBS, trypsinized, pelleted (200x g, 3 minutes) and re-
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suspended in full DMEM with 2µM JC-1 (Biomol, Germany) and incubated for 
15 minutes. Subsequently cells were pelleted again, and resuspended in 
DMEM without phenol red (colourless), transferred into round-bottom 96 a well 
plate and analysed. The mean values of red and green fluorescence of each 
population were calculated and the mitochondrial inner membrane potential 
was then quantified as a ratio of mitochondrial aggregated to free (cytosolic) 
JC-1 red/green fluorescence.   
   
SRB Survival and growth assays  
The total-protein based SRB colourimetric assay was used to assess cell survival 
and growth upon genetic alterations, small molecule treatments and medium 
conditions alterations. SRB sulforhodamin-B, is a water-soluble dye that 
stoichiometrically binds to proteins in weak acidic conditions. In alkaline conditions, 
this SRB-protein bond is destabilized and the dye is released and dissolved into the 
solution allowing colourimetric determination of the amounts of bound SRB, and thus 
the correlating amount of total proteins reflecting cell density. These properties are 
exploited in the SRB growth/survival assay, in which viable adherent cells are first 
fixed onto the cell-culture modified surface and then measured using the following 
protocol derived from Vichai and Kirtikara 2006 [83]. 
Cells were cultivated in 96 well plates at a density of 5000 or 10000 cells/well with 
150 µl medium per well, unless otherwise indicated. In case of small-molecule 
treatments, cells were incubated for 24 hours following seeding and then treated with 
a 1:1 serial dilution using the VIAFLO ASSIST automated system (Integra 
Biosciences, Biebertal, Germany). Treatments were performed in triplets or 
quadruplets. Co-treatments were performed at a constant concentration combined 
with the ascorbate gradient. At the indicated time intervals, cells were fixed by adding 
half a volume (75 µl) of pre-chilled 10% tricholroacetic acid TCA and incubating at 
+4° for 1 hour at least. Subsequently, the plates were washed with deionised water 
three times and then dried for 20 min at 60°c. Afterwards, 75 µl of SRB and 1% 
acetic acid solution was added into each well and incubated for 30 minutes in the 
dark. Subsequently, all wells were washed twice with 1% acetic acid solution and 
plates were then dried for 20 min at 60°c. Finally, 150µl of 10 mM Tris (pH=10.5) 
were added and plates were shaken at 450 rpm for 5 minutes to dissolve the SRB 
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dye. The absorption of SRB was measured at 535 nm using the Tecan-Ultra 
microplate reader. Optical-density reads were then normalized to the non-treated and 
the resulting survival curves were plotted using GraphPad Prism.  
 
LC-MS Metabolic flux analysis of MCF-7 cells:   
Cells were seeded in 6 well-plates at 300.000 cells/ well. After 24 hours, media were 
replaced and cells were further incubated for 16 hours. Subsequently, media was replaced 
with fresh media. After 4 hours, cells were washed with ice cold PBS and metabolites were 
extracted in 1 mL of methanol/acetonitrile/H2O (2:2:1). Samples were shaken for 10 minutes, 
centrifuged for 15 minutes at at 4 °C and supernatants were collected for LC-MS analysis. 
LC-MS analysis was performed on an Exactive mass spectrometer (Thermo Scientific) 
coupled to a Dionex Ultimate 3000 auto-sampler and pump (Thermo Scientific). Metabolites 
were separated using a Sequant ZIC-pHILIC column (2.1 x 150 mm, 5 mm, guard column 2.1 
x 20 mm, 5 mm; Merck) using a linear gradient of acetonitrile (A) and eluent B (20 mM 
(NH4)2CO3, 0.1% NH4OH in ULC/MS grade water (Biosolve)). Flow rate was set at 150 
ml/min and the gradient ran from 20% B to 60% B, followed by a wash step and equilibration 
at 20% B. The MS operated in polarity-switching mode with spray voltages of 4.5 kV and -
3.5 kV. Metabolites were identified on the basis of exact mass within 5 ppm and further 
validated by concordance with retention times of standards. Quantification was based on 
peak area using LCquan software (Thermo Scientific) Peak intensities were normalized 
based on median peak intensity.  
 
Extraction of mRNA from cultured cells 
Cells were seeded in full DMEM in six-well plates at a density of 2x105 cells/well. 
After 1 day cells were treated, or transfected as indicated, and after the indicated 
duration of treatment mRNA was extracted using the following triazole/chloroform 
protocol:  
- Medium was aspirated and cells were washed with 2 ml PBS.  
- 200 µl Triazole (Sigma-Aldrich) were added directly onto the cells, and cells 
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were thoroughly scratched.  
- The triazole was incubated on top of the cells for 5 minutes at room 
temperature. 
- The Triazole lysates were aspirated and transferred into fresh Eppendorf 
tubes.  
- 40 µl of chloroform were added to each tube.  
- Tubes were vortexed for 15 seconds each, and then incubated for 15 minutes 
on ice.  
- Tubes were centrifuged at 12000 x g for 15 minutes at 4°C to fully separate 
the aqueous and chloroform phases, with the genomic DNA condensed on the 
interface.  
- The RNA-containing upper aqueous layer was transferred into fresh 
Eppendorf tubes.  
- 100 µl of isopropanol were added to each tube to precipitate the RNA. 
- Tubes were incubated for 10 minutes at room temperature.  
- Tubes were centrifuged at 12000 x g for 4 minutes at room temperature, 
washed twice with 500 µl 70% ethanol.  
- RNA was pelleted by centrifugation at 7500 x g for 5 minutes at 4°C. 
- Pellets were air dried under laminar flow bench and the RNA was dissolved in 
20 µl of nulcease-free water.  
 
Complementary DNA (cDNA) synthesis 
The synthesis of cDNA from the isolated RNA was carried out using the ProtoScript® 
First Strand Synthesis kit from NEB®. 
The cDNA was synthesised using the protocol provided with the kit. To ensure that 
the mRNA is exclusively reverse-trscribed without other RNA types in the mixture, the 
reverse transcription was performed using poly-t primers that anneal specifically to 
the poly-A tails of the mRNA transcripts.   
 
Real-time quantitative PCR rt-qPCR 
For the quantitative PCR the LightCycler® Sybr Green (Roche®) reaction mix was 
utilized. The reactions were prepared according to the following protocol:  
 The following master-mix was prepared for each primer pair (target gene) to 
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be tested. Quantities are giver for 1 reaction:  
- Cybr Green®: 2.5 µl 
- Primer Mix: 1 µl 
- Nuclease free water: 0.5 ml 
Pipetted onto 1 µl of cDNA (concnetration≈30 ng/µl) 
The tested cDNAs were pipetted in Microplate 96 LP (Analytik Jena AG) compatible 
to the qTOWER real-time PCR thermal cycler (Analytik Jena AG).  
4 µl of the master-mix were pipetted in triplets on each type of the tested cDNAs. 
Subsequently, the plates were fed into the qTower real-time PCR thermal cycler, 
where the reactions occurred and the results were obtained.  
 
Quantitative interpretation of the qPCR data 
The mean values of the yielded CT of each triplet or reactions were calculated, 
including the mean-values of each tested cDNA with the reference genes. Then using 
these mean values of the CT of each target and reference genes, relative expression 
of the target genes was compared for the different cDNAs (treated vs non-treated or 
transfected vs empty vector) using the ∆∆CT equation to yield the relative expression 
values:  
∆Ct=Ct(target gene)-Ct(reference gene) for a given sample.  
∆∆Ct=∆Ct(treated sample)-∆Ct(control sample) 
Relative expression (Fold change)=-2∆∆Ct 
 
Transcriptional profiling of MDA-MB231 cells 
RNA was extracted from 500.000 cells. RNA concentrations were adjusted to 
100ng/µl and samples were sent to collaborators in the Functional Genome Analysis 
Devision in DKFZ (Lab of Professor Jörg Hoheisel), were they were analysed using 
the Illumina RNA microarray system. The utilised method was described in previously 
published research from the group [84]and is summarised below:  
- RNA-integrity of the samples was verified using Agilent 2100 Bioanalyzer  
(Agilent Technologies, Palo Alto).  
- The analysis of the total RNA in the samples was performed using Sentrix 
Human-6v3 Whole Genome Expression BeadChips (Sentrix Human WG-6; 
Illumina). 
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- Following hybridisation to the chips according to the manufacturer’s 
instructions, the arrays were scanned with a BeadArray Reader (Illumina). 
 
Colony forming assay 
Yeast 
In yeast this assay was used to assess the intact cell-fractions upon long term MMS 
treatment by assessing the percentage of cells capable of giving rise to a colony 
upon MMS exposure.  
Overnight cultures in SD-Ura were first diluted to an OD600 of 0.2 and incubated for 5 
hours till it reached mid-log phase. Each culture was then split into three parts, non-
treated and treated with 0.02% and 0.03% MMS. Following 12 h of shaking at 30°C, 
cultures were diluted and cell density of all samples was adjusted to OD of 0.5. 
Subsequently, the adjusted suspensions were used for both PI-staining and colony 
formation assay. The adjusted cell suspensions of non-treated samples were diluted 
1:1000 (three step serial dilution 1:10) then 50 µl of each diluted sample were spread 
on an SD-Ura agar plates. Adjusted suspensions of cells treated with 0.02% MMS 
were diluted 1:10 and then 50 µl of each diluted sample was spread on an SD-Ura 
agar plate. The agar plates were incubated for 48 h at 30° then colonies were 
manually scored. This experiment was repeated three times independently. 
Cell culture 
Cells were seeded in 6 well plates at the extra-low density of 300 cells/well in 2 ml full 
DMEM. Any treatment, if included, was started 3 days after seeding. After 2 to 3 
weeks of incubation colonies were fixed, stained and visualised according to the 
following protocol.  
- The culture medium was aspirated and cells were washed in 2 ml PBS.  
- Colonies were fixed and stained using a PBS solution containing 0.021% (v/v) 
formaldehyde and 0.5% (w/v) crystal violet.  
- Following 30 minutes of incubation in the dark at room temperature, the staining 
solution was aspirated and all wells were rinsed 3 times in sterile water.  
- Stained colonies were imaged using a regular camera. 
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III Results 
 
“There is nothing like first-hand evidence”. Sherlock Holmes (Arthur Conan Doyle) 
 
III-I Investigating the mechanism behind FBP1 MMS-sensitizing effect in 
S.cerevisiae 
It has already been shown that FBP1 is transcriptionally induced upon MMS 
treatment. Several FBP1-related aspects can affect the response of yeast cells 
towards MMS-induced DNA-damage. These include the catalytic activity of the 
expressed enzyme, the altered RedOx balance as reflected by decreased post-MMS 
ROS accumulation in absence of FBP1, in addition to a plethora of possibilities 
including the potential non-catalytic interactions and effects of metabolic by-products.  
To further probe this relationship between Fbp1 and MMS-sensitisation I screened a 
library of Fbp1-analogues with point mutations targeting evolutionary-conserved 
residues of functional and mutational relevance. Each mutant had one amino acid 
replaced for alanine (alanine screening). The evolutionary conservation over long 
phylogenic distances points out to functional constraints preserving the conserved 
residues. Enzymes catalysing the same reactions exhibit much higher conservation 
on the level of amino-acid sequences compared to the nucleotide sequence. This is 
because silent mutations within evolutionary conserved codons are tolerated.  
III-I-1 Selection of amino acid residues for mutational analysis 
“This passage is based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
To investigate the relevance of evolutionary conserved residues to the catalytic 
and MMS-sensitiing activities of Fbp1, we prepared fbp1 over-expression vectors, 
each containing a single mutagenised codon of a conserved residue. The global 
alignment of primary amino-acid sequences of Fbp1 orthologues from several 
species including Homo sapiens and Saccharomyces cerevisiae revealed 46% 
identitiy Fig.1 [86, 87]. We therefore were confronted with a large choice of 
conserved residues as candidates for our mutagenesis screen. Hence we relied 
upon previous evidence from various structural and functional studies on yeast 
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and mammalian Fbp1 orthologues to define the residues with the highest 
likelihood of participation in the dual role observed in yeast.  
An overall glance at the aligned sequences of yeast vs human FBP1 amino-acid 
sequences reveals a fully heterologuos N-terminus that extends in the yeast 
orthologue for 9 additional residues, for which no counterparts are present in the 
mammalian protein [87]. This “overhang” has been implicated in the glucose-
triggered post-translational degradation “catabolite inactivation” of FBP1 in yeast, the 
N-terminal Pro1 residues is involved in recruiting specific proteases to the 
ubiquitinated protein according to the N-end rule [88, 89]. The phophorylation of 
Ser11 by cAmp mediates the loss of FBPase activity upon glucose replenishment. 
[90]. The residues 52-72 in the mammalian orthologues, homologues to 63-82 in 
yeast participate in the formation of a loosely structured loop with a crucial effect on 
the finally tertiary structure of the FBP1 homo-tetramer. The interaction to AMP 
disrupts the interaction between the loop and the active site and thus leads to the 
inactive T-state confirmation, while in absence of AMP from the structure this loop 
orients towards the active site permitting the participation of Asp79 (yeast) 
Asp68(mammals) in the catalytic activity. This mechanism allows the energy 
regulation of gluconeogenesis [91] (Fig 1.I c) The above mentioned loop contains two 
evolutionary conserved residues. The first, Asn(64 mammals, 75 yeast) participates 
in the formation a water-water binding pocket along with two other evolutionary 
conserved residues Asp (74 mammals 85 yeast) and,  Glu (98 mammals, 109 yeast).  
The water molecule bound to this pocket facilitates the nucleophilic attack of another 
neighbouring water molecule on the phosphate-group at 1`position of the substrate 
F1,6bP, which eventually splits the substrate into Fructose-6-phosphate F6P and 
inorganic phosphate group iP. The second, Asp(68 mammalis, 79 yeast), aligns 
towards the active site and promotes the movement of a proton from the phosphate 
group at 1` towards an OH group in the product F6P [91].  
A stretch of evolutionary conserved residues Asp118 to Ser 123 in mammals and 
Asp128 to Ser133 in yeast forms a divalent-cation binding site essential for the 
enzymatic catalysis (Fig 1.I b). This metal binding pocket is conserved through all 
Fbp1 orthologues. Moreover, a homologues metal bindings site is encountered in 
various other phosphatases similarly requiring metal cationic co-factors [92]. 
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Mammalian and yeast Fbp1 orthologues share the exact same sequence comprising 
this metal binding pocket Asp-Pro-Ile-Asp-Gly-Ser [92].  
Phe(185 mammals, 194 yeast) is an evolutionary conserved residue within a 
conserved stride of other amino-acids. Due to the bulkiness of phenyl-alanine in 
addition to its middle position in Fbp1, we considered a key-effect of this residue on 
protein folding plausible and included it in our mutagenesis screening.  
The c-terminal region of FBP1 comprises the largest evolutionary conserved regon of 
this protein, exhibiting 66% identity between yeast and mammalian orthologues. This 
region extends between Asp 243 and Ser321 in mammals and Asp254 and Ser333 in 
yeast and it also contains the catalytically active site (substrate-binding pocket), this 
knowledge has been recently harnessed in studies on human cancerous cells as well 
[61, 93]. The c-terminus includes two evolutionary-conserved histidines His265 
(yeast) and His324 (yeast). Due to their amphephilic nature, and presence near the 
active site, these two residues are likely to contribute to catalysis.  
Based on the summarised structural and functional knowledge we chose 9 
candidates for out alanine-screening, in which we mutagenised the targeted residues 
by introducing point mutations converting their respective codons to those of alanine.  
In the results and discussion pertaining to this mutational screening, I will refer to 
each mutation by the three-letter symbol of the mutagenised (alanine-replaced) 
amino-acid and its respective number in the amino-acid chain of the yeast 
orthologue.  
Based on the summarised knowledge, 9 residues were chosen for the alanine 
screening. A point mutation was introduced to alter the codon of each targeted 
residue into an alanine codon. In the following results and discussion pertaining to 
this mutagenesis screen, each mutation was referred to using the three-letter symbol  
of the amino-acid and its respective number in the amino-acid chain of the yeast 
homologue. Table 9 features the screened mutations, along with their abbreviations 
and the utilised mutagenesis primers.  
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Table 9: Summary of the analyzed yeast fbp1 mutations and the utilized 
mutagenesis primers 
Mutations 
(Altered 
residue) 
Mutagenesis primers Abbreviation of the 
mutated FBP1 form  
Pro1!Ala1 fw: GGATTCTAGAACTAGTATGGCAAC TCTAGTAAA TGGACC  
rev: GGTCCATTTACTAGAGTTGCCATACTAGTTCTAGAATCC 
Pro1 
Asn75!Ala75 fw: GTTAGCAGGCGCTTCCGCCTTCACTGGTGACCAGC 
rev: GCTGGTCACCAGTGAAGGCGGAAGCGCCTGCTAAC 
Asn75 
Asp79!Ala79 fw: GCTTCCAACTTCACTGGTGCCCAGCAAAAGAAGTTGGAC 
rev: GTCCAACTTCTTTTGCTGGGCACCAGTGAAGTTGGAAGC 
Asp79 
Glu109!Ala109 fw: GGTCCTTGTATCTGAAGCACAGGAAGATTTGATCG 
rev: CGATCAAGTCTTCCTGTGCTTCAGATACAAGGACC 
Glu109 
Asp131!Ala131 fw: GTGTGTTGTGATCCTATTGCTGGCTCCTCAAATTTGGAC 
rev: GTCCAAATTTGAGGAGCCACGAATAGGATCACAACACAC 
Asp131 
Ser133!Ala133 fw: GTGATCCTATTGATGGCGCCTCAAATTTGGACGCCGG 
rev: CCGGCGTCCAAATTTGAGGCGCCATCAATAGGATCAC 
Ser133 
Phe194!Ala194 fw: GGTGATGGAGTTGATGGGGCTACCTTAGACACAAACTG 
rev: CAAGTTTGTGTCTAAGGTAGCCCCATCAACTCCATCACC 
Phe194 
His65!Ala265 fw: CCATGGTTGCTGATGTTGCCAGGACGTTTCTTTACGG 
rev: CCGTAAAGAAACGTCCTGGCAACATCAGCAACCATGG 
His265 
His324!Ala324 fw: GATTTGGTGCCAAGTCATACCGCTGACAAATCTTCTATT 
rev: AATAGAAGATTTGTCAGCGATATGACTGGCACCAAATC 
His325 
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Figure 1 featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
Figure 1: multiple global-alignment of FBP1 amino-acid sequences of Saccharomyces cerevisiae and 
several species using the online-available ClustalW2 multiple sequence alignment tool, provided by 
EMBL-EBI. 
Identical residues are marked with (|) ; similarities (:) and totally different ones with (.) 
Residues included in the mutational analysis are highlighted.  
Three regions (a, b and c) of sequence homology are indicated: (a) representing the mostly conserved 
part of the regulatory loop, (b) the conserved metal binding site, and (c) the largest homology domain 
on the c-terminus containing the active site. 
Mutated residues highlighted.  
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Figure 1.I: Structural relevance of the mutated residues. 
a) The FBP1 tetramer with the mutated residues annotated. b) FBP1 monomer featuring the mutated 
residues, with focus on the cation binding motifs and the adjacent targeted residues. c) Monomeric 
structure of FBP1 and the oscillation between the t and r states. This figure was created based on se 
from the NCBI Structure Database and the Structure Cn3D software tool was used to render the 
structures and label the mutated residues.   
 
 
 
III-I-2 Detection of expression of Fbp1p mutants from expression cassettes 
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“This passage is based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
The protein expression of 6 out of the 9 tested mutants was successfully detecgted in 
both the cytosole and the nucleus of the Fbp1-deficient strain fbp1∆. Meanwhile, the 
two Phe194 and His 265 mutants were only present in the nucleus. Only one mutant 
Asp79 remained undetected in either the cytosolic or nuclear fractions (Fig2 a) The 
semi-quantification of western-blot band-intensities indicated an effect of some of the 
mutagenised residues on the nuclear/cytosolic sub-cellular localisation of FBP1 
(Fig.2 b). Beside Phe194 and His265 leading to exclusive nuclear sub-localisation, 
three mutants (Asp131, Ser133 and His324) also tilt the balance towards the nuclear 
localisation. In contrast, Pro1 and Glu109 favour cytosolic sub-localisation of FBP1.  
 
 
This figure featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
This immunoblot was performed by Jinda Holzwart as part of her Diploma thesis. 
Figure 2: Immuno-detection of the over-expressed Fbp1p mutants.  
a) Western-blot showing the levels of the over-expressed mutants in both cytosolic and nuclear 
fractions. Over-expression was verified in absence of endogenous Fbp1p expression in fbp1∆ strains. 
PGK1 and NOP1 were utilized as cytosolic and nuclear loading controls, respectively. b) Quantification 
of the western-blot signals, each band was normalized to the intensity of its loading control, resulting 
values where then normalized to those of the wt.  
III-I-3 Catalytic activity of the Fbp1p mutants 
“The following passage based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
To assess the effect of altered residues on the catalytic activity of Fbp1 we over-
expressed the mutated proteins in a haploid wild-type BY4741 strain and quantified 
the resulting increase in the FBPase catalytic activity in the crude native protein 
lysates of the mutant-expressing strains compared to the strain harbouring the 
corresponding empty vector. This revealed that the screened mutants clustered into 
three distinct groups in relation to their catalytic activity (Fig. 3): 
- Pro1 and Asn75 bestowed similar increase of the FBPAase activity to that seen 
with the wild-type FBP1.  
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- Phe194, His265 and His324 all show partial increase in the enzymatic activity of 
around 50% of that of the wild-type enzyme.  
- Asp79, Glu109, Asp131 and Ser 133 all resulted in no increase in the FBPase 
activity, and the strains harbouring these mutants had similar FBPase activity to 
the wild-type. 
 
Figure 3 featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
This figure is based on enzymatic activity measurements of mutated Fbp1 performed by Jinda 
Holzwarth as part of her Diploma thesis.  
Figure 3: Enzymatic activity of the utilized FBP1 mutants:  
FBPase catalytic activity was measured in native lysates of wild-type BY4741 strains with over-
expression of wild-type and mutated fbp1 cassettes. Measurements were performed in triplets, and 
error bards represent SD.  
Statistical significance was determined using student t-test for each of the mutants compared to both 
cells with control vector and those with over-expression of the wild-type Fbp1p. (*) Indicates 
statistically relevant difference compared to empty vector and (†) compared to the wild-type Fbp1p.  
 
III-I-4 Rescue of growth on non-fermentable medium (Spot-assay on SDEG) 
“The following passage based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
 To probe the capacity of the screened mutants to replace the deleted endogenous 
expression of FBP1 and rescue gluconeogenesis in fbp1∆ cells was assessed. This 
was done by assessing the growth of fbp1∆ strains over-expressing individual 
mutatagenised cassettes on a non-fermentable medium. The non-fermentable 
medium SDEG contains ethanol and glycerol as exclusive carbon sources and thus 
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only permits the growth of cells with a functional gluconeogenesis pathway. The spot 
assay on SDEG-agar yielded the predictable observation that Fbp1 catalytic activity 
is indispensible for proliferation on non-fermentable carbon sources. The four 
mutations that completely attenuate the catalysis; Asp79, Glu109, Asp131 and 
Ser133, also abrogated growth on SDEG (Fig.4 a). In contrast mutants partially or 
fully spraining the FBPase activity; Pro1, Asn75, Phe194, His265 and His 324, were 
able to rescue the growth on SDEG in the absence of endogenous (Fig.4 a).  
III-I-5 Sensitivity to low doses of MMS 
“The following passage based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
Since it had been demonstrated that MMS-exposure induces fbp1 transcription, and 
that the presence of the endogenous Fbp1 is decisive for the sensitivity towards low 
doses of MMS [94], I used the established mutant library to screen probe the 
connections of the additional MMS-sensitisation role to the mutated evolutionary 
conserved key-residues of this enzyme. For this purpose, the mutagenised proteins 
were expressed in both wild type and fbp1-deficient (fbp1∆) BY4741 genetic 
backgrounds. The resulting strains were cultivated in liquid media, then serially 
diluted and spotted on SD-Ura agar containing low concentrations of MMS increasing 
from 0.01% to 0.0175%. The spot-assay agar plates were surveyed following 48 
hours of incubation. Predictably, the inactivating mutations Asp79, Glu109, Asp131, 
Ser133 and His324 also attenuated the additional FBP1-induced MMS-sensitisation, 
yielding strains with similar growth on MMS to that of wild type stain with an empty 
vector (Fig. 4 b to i). In contrast, three enzymatically active mutants maintained the 
MMS-sensitising effect as they correlated to further growth inhibition on MMS-agar 
similar to ectopically expressed non-mutated FBP1 (Fig. 4 b to i). Intriguingly, 
mutagenising Asn75 abrogated the MMS-sensitisation (Fig. 4 b to i) despite 
maintaining almost the full catalytic activity of the non-mutated enzyme (Fig.3). 
Hence this mutant seems to decouple the catalytic activity of FBP1 from its ascribed 
role in increasing sensitivity towards low MMS concentrations. Similar growth 
tendencies were observed for the mutant-harnouring strains with wild type and 
fbp1∆ genetic backgrounds. Importantly, the fbp1∆ strains exhibited less sensitivity to 
all tested MMS concentrations in contrast with their wild type counterparts. Hence 
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confirming earlier findings that fbp1 deletion bestows cells with increased resistance 
towards MMS [94]. The direct observations from the spot-assays were further 
confirmed using spot-intensity quantification (Fig. 4 f, g, h and i). 
 
Figure 4 featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
Figure 4: Drop-tests on Non-fermentable (SDEG) and MMS-containing agar-media.  
a) Drop-test on SDEG non-fermentable medium. WT and mutated FBP1 cassettes were introduced 
into BY4741 fbp1∆ cells lacking endogenous FBP1, the resulting strains were grown in liquid SD-Ura 
medium, diluted and spotted on SDEG, same suspensions were spotted on SD-Ura agar as a control. 
Agar-plates were incubated for 48 hours at 30° 
b&c) Drop tests on SD-Ura agar with 0.01% MMS. Mutants and wild-type cassettes were introduced 
into both WT (a) and ∆fbp1 (b) BY4741 cells. The resulting strains were grown in SD-Ura and then 
diluted (1:5) and spotted on freshly prepared SD-Ura containing 0.01%, and on SD-Ura as non-treated 
control. Agar plates were incubated for 48 h at 30° for 48 h.  
d&e) Drop tests on SD-Ura agar containing 0.015% and 0.0175% MMS. Plates were incubated for 72 
h at 30°. 
f to i) Quantifications of the spot-intensities of the drop tests on SD-Ura 0.01% MMS second and third 
spots (OD600: 2 and 0.4 respectively) and 0.0175% first and second spots (OD600: 10 and 2 
respectively). Featured results are taken from three biologically independent replicates, (error-bars: 
SD; N=3)  
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III-I-6 Over-production of Fbp1p sensitises cells to MMS in liquid medium 
“This passage is based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
To further address the MMS-sensitising effect of Fbp1, the growth of yeast strains 
with variable Fbp1 contexts was evaluated in MMS-containing liquid SD-Ura. Pre-
cultures of the tested strains were incubated over-night in SD-Ura, following dulitions, 
cultures were then preincubated for 3 hours prior to treatment. The treatments were 
performed in triplets in a 96 micro-titer plate format, with 0.01% and 0.02% MMS. 
Upon treatment OD600 was measured over the course of 24 hours in a microtiter plate 
reader. The exposure to 0.02% MMS had a uniform severe growth inhibitory effect on 
all tested strains. Meanwhile, the effect of the lower concentration 0.01% was largely 
determined by the context of Fbp1 expression in the cells. The ectopic introduction of 
a catalytically active form of Fbp1 (wild type or active mutant) increased the 
sensitivity towards 0.01% MMS and correlated to a lower growth over time (Fig 5, a 
to g). The wild type enzyme and active mutants Asn75 and His265 all significantly 
obstructed growth when ectopically expressed in a wild type genomic background 
(Fig. 5, a e and g). The inactive mutant Asp131 lacked this effect, and cells still 
achieved a similar growth to those harbouring an empty vector (Fig. 5, a and F). Also 
noteworthy is the contrast in the outcome of Fbp1 ectopic expression according to 
the presence of endogenous Fbp1. Predictably, the presence of endogenous Fbp1 
potentiated the MMS-sensitising effect seen with over-expressed catalytically active 
Fbp1. And while cells with wild type background and over-expression of Fbp1 
seemed to undergo permanent inhibition of growth, those with an fbp1∆ genotype, 
only suffered growth retardation upon 0.01% MMS treatment, and still matched the 
OD600 of the non-treated cells at a later point (Fig.5 A to D).  
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Figure 5 featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
Figure 5: Growth curves upon MMS treatment: 
Figures a to g feature the growth curves of the non-treated and MMS-treated (0.01% and 0.02%) yeast 
strains in liquid SD-Ura medium. Curves feature the increasing OD600 values over-time at 30° with 
intermittent shaking, error bars represent SD, N=3.  
 
 
III-I-7 The effect of Fbp1p over-production on cell survival depends on its 
genomic context of fbp1 
“The following passage based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
To determine the effect of Fbp1 on cell survival upon MMS treatment I used FACS of 
propedium-iodide PI stained cells. Log-phase liquid cultures in SD-Ura medium were 
treated with MMS for 12 hours. The FACS analysis showed an increase in dead cell 
fractions upon 0.02% and 0.03% MMS treatment in all tested strains (Fig.6 a and b).  
The effect of ectopic Fbp1 was completely dependent on the presence of 
endogenous expression. Only in wild-type cells did the over-expression lead to 
decreased survival upon MMS treatment, seen as increased in PI-positive dead-cell 
fractions of treated populations. Over-expressed Fbp1 lacked this sensitising effect in 
absence of its endogenously expressed counter-part (in fbp1∆ cells). Both the Asn75 
and His265 mutants failed to reproduce the effect of the ectopically introduced wild 
type enzyme in increasing cell death upon MMS-exposure (Fig. 6 a). 
Interestingly, the ectopic over-production of Fbp1 correlated to improved cell survival 
and diminished PI-staining both in absence and presence of endogenous expression.  
This side observation consists with previous findings of an improved chronological 
life span associated to Fbp1[94].   
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III-I-8 Over-production of Fbp1p hampers colony-forming capacity upon MMS 
treatment 
“The following passage based on my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
To further investigate cell survival upon MMS treatment, we tested the impact of wild 
type and mutated forms of Fbp1p on the colony forming capacity of cells following 
MMS treatment. Generally, 12 hours of 0.02% MMS treatment lead to a two to three 
orders of magnitude decrease of the colony forming units CFU/µl (Fig. 6, c and d). In 
the context of WT cells with endogenous Fbp1p expression, this decrease was 
strongest when wild-type Fbp1p or the active mutant His265 were over-expressed 
(Fig. 6 c). In contrast, over-expression of wild-type Fbp1p in cells lacking the 
endogenous gene (fbp1∆) had no further inhibitory effect on colony forming capacity 
(Fig. 6 D). It is also worth noting that in the WT strain, over-expression of Fbp1p or its 
active mutant His265 lead to significant decrease in CFU/µl in the non-treated 
samples as well, compared to non-treated cells harbouring the control vector. 
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Figure 6 featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
Figure 6: Cell survival and colony formation upon MMS treatment.  
a&b) FACS analysis of PI staining following 12 hours of MMS treatment.  
Bars represent the PI-positive percentage fractions of cells as measured using FACS.  
Results feature three biologically independent replicates with three technical replicates each. Error 
bars show the standard deviation.  
Statistical significance was determined using unpaired student t-test assuming equal variance.        
(*: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001)  
The brackets over the wt Vector ,fbp1∆ Vector strains and the control vector strains show the 
significance difference between treated and non-treated samples within the same strain. While 
asterisks over the mutants represent statistical significance when comparing the results of these 
strains with those of the control vector.  
c&d) colony formation on SD-Ura agar following 12 hours of MMS treatment in liquid SD-Ura. Results 
are from 3 independent experiments. Error bars show the standard deviation. Asterisks indicate 
statistically significant differences compared to the control vector strains. Significance was assessed 
using student t-test (*: p<0.05)  
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III-I-9 FBP1 loss curtails ROS induction and correlates to an induced anti-
oxidant capacity 
Previous reports demonstrated that FBP1 absence reduces post-MMS ROS-
accumulation. This was shown to occur one hour after treatment (Reference ??). To 
further verify and extend this finding, ROS levels were measured following longer-
term treatments (18 hours) with a lower dose (0.01%) of MMS. Fluorescent images of 
DHE-stained cells showed that the ectopic over-expression of FBP1 clearly 
correlated to higher levels of ROS upon MMS treatment. That was the case in the 
presence or absence of endogenously expressed Fbp1 (wild type and ∆fbp1 cells) 
(Fig.7 i). Moreover, Fbp1 over-expression induced ROS accumulation in non-treated 
cells following the 18-hour incubation. This effect was stronger in wild type cells over-
expressing Fbp1 compared to Fbp1 deficient cells. To further quantify similar 
observations related to Fbp1 effects on ROS accumulation, I used microtiter plate 
reader to quantify DHE fluorescence. Since long incubation time would allow for big 
differences in cell density due to unequal proliferation rates. I used GFP fluorescence 
to set DHE signals to the scale of different cell densities of strains harbouring either 
free GFP or in fusion with Fbp1 (Fig. 7 ii). 
The Fbp1-deficient cells exhibited lower DHE fluorescence compared to wild-type, 
and this was the case for both non-treated and long term (18-hours) MMS treatment. 
Ectopic over-expression of Fbp1 in the ∆fbp1 cells correlates to an increase in ROS 
to levels higher than those of the wild-type strain. Long-term MMS treatment induced 
ROS accumulation in all three different contexts. However, the absence of Fbp1 
partially mitigated the ROS increase upon MMS treatment. Basal ROS levels in the 
wild-type are also lower than those of the fbp1∆ cells, while they were highest upon 
over-expression of Fbp1. This indicates an impact of Fbp1 on the RedOX 
homeostasis independent of the genotoxicity of MMS. Due to its correlation with 
higher ROS accumulation, I speculated an impact of Fbp1 on the cytosolic anti-
oxidant capacity. Glucose-6-phsophate dehydrogenase G6PD catalyzes the 
oxidation of glucose-6-phosphate to 6-phosphogluconolactone gluconalactone with 
NADP+ as a co-factor that gets reduced into NADPH. Additionally, this reaction is the 
first committed step in pentose phosphate pathway PPP, which generates one more 
NADPH in its last oxidative step. This makes G6PD the major cytosolic source of 
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NADPH. NADPH plays a pivotal anti-oxidant role in the cytosol via providing the 
reducing equivalents required for maintaining glutamine in a predominantly reduced 
form. By measuring G6PD activity in native protein lysates, Fbp1-deficient cells 
exhibit increased base-line G6PD activity, and also a stronger induction of G6PD 
catalytic activity in response to MMS. This increased G6PD induction gives the Fbp1 
deficient cells an edge over the wild-type cells due to the induced flux through PPP. 
In addition to the aforementioned anti-oxidant capacity the PPP is also the only 
intracellular source for ribose synthesis needed for DNA repair pathways, including 
base-excision repair thought to be of importance following MMS-exposure.  
This points out a contribution of excess (raised) G6PD in increasing tolerance 
towards MMS in the Fbp1-deficient cells.  
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Figure 7: Fbp1 induces increased ROS accumulation upon MMS exposure:  
i) Fluorescent microscopy images depicting DHE red fluorescence of yeast strains with varying Fbp1 
expression 20 hours following MMS exposure. ii) Bar charts depict the fluorescence levels of DHE of 
GFP-harbouring yeast strains with various Fbp1 expression. DHE signals were normalized to 
measured GFP fluorescence (correlating to the cell density). iii) G6PD activity measured in wild-type 
and Fbp1-deficient strains 4 hours following MMS treatment.   
 
III-II The Effects of Fbp1 in Cancers 
Emphasis on the importance of increased glycolytic flux had been defining our 
understanding of tumour metabolism. Only recently, light had been shed on the 
aberrant regulation of gluconeogenesis as a contributing factor to the metabolic 
reprogramming that allows malignant transformation. Increasing evidence from 
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different types of tumours points out to the repression of FBP1 in tumours compared 
to adjacent normal tissues. Epigenetic silencing of Fbp1 occurs as part of 
tumerigenesis in liver, colon, gastric, pancreatic and renal cancers. These tumours 
show an overall repression of FBP1, while breast cancers are heterogeneous in 
regards to their expression of Fbp1. On the direct enzymatic level, the loss of Fbp1 in 
cells confers a metabolic advantage onto the cells by allowing the uncontested flux of 
metabolites through the glycolytic pathway. Additionally, several reports also 
indicated non-catalytic ways through which Fbp1 loss indirectly contributes to tumour 
metabolic reprogramming or further gain of aggressiveness and invasiveness. An 
inhibitory interaction of Fbp1 with Hilf1α in the nucleus has been observed, which is 
independent of the catalytic function. Consistently, Fbp1 expression has been 
relatively correlated to Hif1α levels in breast cancer cell lines [61]. The benefits 
bestowed upon tumours via Fbp1-loss are experimentally reversible by ectopic 
replenishment of the silenced FBP1, or by epigenetically repressing it as very 
recently reported in hepatocellular carcinoma cells [95].  
 
III-II-1 The significance of FBP1 in the context of Breast Cancer (Back-ground) 
Breast cancers make an interesting model for understanding the effects of FBP1 on 
cancer metabolism and aggressiveness in general. This is because breast tumours 
are heterogenous in regards to their FBP1 expression [96]. Broadly speaking, breast 
tumours fall into two major categories; ductal breast cancers DBC, and basal like 
breast cancers BLBC. The former are primary tumours, of epithelial morphology and 
are hormone driven exhibiting positive estrogen receptor ER and progesterone 
receptor PR and human epidermal growth factor 2 HER-2 receptors expression[97]. 
The latter are also often called triple-negative-breast cancers TNBC. They are 
distinguished by the lack of the three hormone receptors ER, PR, HER-2, in addition 
to the absence of epithelial markers including E-Cadherin[97]. Compared to ductal 
breast cancers, basal-like breast have a markedly worse prognosis, attributed to their 
invasiveness and metastatic nature. Interestingly, the relationship between the two 
types is a dynamic one. In contrast with the non-metastatic Breast carcinoma in-situ 
BRIC some ductal breast cancers display the capacity of gaining invasive and 
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metastatic features. Eventually this results in metastasis having similar markers to 
BLBC and TNBC, the lack of hormonal receptors and E-Cadherin. To gain 
invasiveness, ductal breast cancers have to undergo a morphological change called 
the epithelial-mesenchymal transition EMT. Simultaneously, further metabolic 
reprogramming occurs to support the requirements of invasiveness and flourishing in 
a new microenvironment, and independently of hormonal stimulation. FBP1 is central 
in this metabolic reprogramming. Primary ductal breast tumours have high levels of 
FBP1, while basal-like tumours and metastases lack it. Furthermore, FBP1 has been 
proven as a target of epigenetic repression during experimentally induced EMT, 
along with the hormonal receptors ER, PR and HER-2 in addition to E-Cadherin [60]. 
Indeed, the ectopic replenishment of FBP1 (under a constitutive promoter) was 
enough to block the EMT progression, maintain detectable levels of the hormonal 
receptors, and rescue the epithelial markers and morphology. In other words, fbp1 is 
silenced as part of EMT, and when rescued FBP1 seems to mitigate the whole EMT 
program and preserve the epithelial morphology [60]. 
 
III-II-2 The breast-cancer cell-culture model to evaluate the effects of FBP1 
As mentioned earlier, my choice of breast cancer cell lines as a model to investigate 
the effects of FBP1 mainly relates to the heterogeneity of breast tumours in respect 
to FBP1 expression, and also to the dynamic changes that occur on FBP1 in the 
contexts of EMT and metastatic events. I therefore started with two breast cancer cell 
lines MCF7, and MDA-MB231. The former a representative of ductal breast cancer, 
while the latter of distant metastatic origin. These two cell lines represent the contrast 
between ductal and primary tumours on the one hand, and basal-like and metastatic 
one on the other. FBP1 is highly expressed in MCF7 cells, while it is completely 
silenced in MDA-MB-231.  The same applies to the hormonal receptors ER, PR, and 
HER-2 and also to the epithelial marker E-Cadherin. Indeed, the morphological 
differences between the two cell lines are simply observable under the microscope, 
as figure 8 clearly depicts.  
To investigate the effects of FBP1 in these cell lines, I cloned the coding sequence of 
the FBP1 gene and established several stable constitutive over-expressions. In 
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addition, I used CRISPR-Cas9 gene-editing to establish deletions of FBP1 in MCF7 
cells.  
 
Fig 8: Microscopic features of the breast cancer cell lines used in this work:  
A and b) MCF-7 cells. C and D) MDA-MB231 cells.  
 
 
 
 
 
III-III The impact of altered FBP1 expression in breast cancer cell lines 
III-III-1: The verification of the established over-expression and deletion in 
MCF7 cells 
Both the over-expression and deletion of this enzyme were established in MCF7 and 
their basal effects on cells were characterized. The stable over-expression and 
deletion were achieved using antibiotic selection and the resulting cells were tested 
for the presence of FBP1 protein and its catalytic function. The tests repeatedly 
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verified the stable alterations in FBP1 levels and catalysis as shown in figure 9. The 
correlation between the increased protein levels in the over-expression cells and the 
increase in FBPase activity, in addition to the complete absence of FBP1 and its 
activity from the deletion cell-type further verifies the reliability of the established 
system for drawing conclusions in regards to the effects of FBP1 and its function on 
the metabolic, proliferative and other addressed parameters.  
 
Figure 9: Verification of FBP1 over-expression and deletion in MCF7 cells.  
a) Western-blots comparing the established stable FBP1 deletion and over-expression cell types to the 
wild type and empty-vector cells, respectively. The blots feature biologically independent triplets of 
each cell type. b) The measured FBPase catalysis in native protein extracts of the stably modified cell 
types-.  
 
III-III-2 FBP1 over-production slows down MCF7 proliferation; the lack thereof 
attenuates proliferation in glucose low/deprived conditions. No visible effect of 
FBP1 on MCF7 capability of colony formation 
I used SRB assays at several time-points to measure the impact of FBP1 on growth 
and proliferation rate of MCF7. The over-expression of the enzyme clearly reduced  
proliferation rate, while the deletion slightly induced it. This was expected due the 
antagonizing effect of FBP1 towards glycolysis in addition to the potential futile 
cycling arising from increased FBPase activity in a glucose rich environment, where 
gluconeogenesis is not required.  
On the other hand, FBP1 is essential for survival in glucose-deprived media. To verify 
this speculation, I measured the growth and proliferation rate of MCF7 cells with 
different FBP1 expression in DMEM media with varying initial glucose concentrations. 
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As figure 10 b clearly shows, the unmodified (WT) MCF7 cells can survive and 
continue to proliferate even after 7 days in DMEM media with reduced (2mM) or 
annulled glucose content. Whilst the FBP1-deficient cells FBP1∆/∆ seize to proliferate 
following 5 days in 2 mM glucose and as soon as 3 days in glucose-deficient DMEM. 
In both cases (0 and 2 mM glucose) FBP1-deficient cells perished following one 
week of incubation. The over-expression of FBP1 only leads to a very marginal 
increase in proliferation in glucose reduced or deficient media. Contrary to my initial 
expectations, FBP1 over-expression or depletion had no visible effect on the capacity 
of MCF7 to form colonies in full DMEM medium.  
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Figure 10: FBP1 effects on proliferation and colony formation:  
a) SRB proliferation assays of the oeFBP1 vs empty-vector cells (left) and of the FBP1∆/∆ vs wild-type 
(right). All measurements were performed with at least 6 replicates with error bars showing SD. 
 b) SRB proliferation assays with varying glucose concentrations c) colony forming assay in full DMEM 
(3 weeks).  
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III-III-3 The over-production of FBP1 limits glucose sensitivity and uptake in 
MCF7 cells, while the deletion of FBP1 winds up the flux through glycolysis 
and pentose phosphate shunt 
It has been postulated that FBP1 slows down glycolysis both by enzymatically 
competing with glycolysis and also by other non-catalytic mechanisms. Therefore, I 
used fluorescence-labelled glucose (2-NBDG) to probe the effects of FBP1 on 
glucose uptake in MFC7 cells. The over-expression of FBP1 clearly inhibits glucose 
uptake in full DMEM. In contrast the deletion of FBP1 does not affect glucose uptake 
(Fig 11 a). To test the effect of FBP1 over-expression on dynamic glucose sensing in 
MCF7 cells, I compared glucose uptake in MCF7 cells over-expressing FBP1 to cells 
harbouring the control vector following glucose starvation/replenishment and also in 
glutamine-free DMEM (Fig. 11 b). Glucose depletion induces metabolic stress in cells 
and consequently activates AMPK. This in turn leads to a shift from glycolysis to TCA 
and oxophos fuelled by glutamine. Upon glucose replenishment, cells sense and 
take-up glucose eventually reducing the metabolic stress, and cells shift back to 
glycolysis. Glutamine depletion in turn, deprives the TCA from an important 
precursor, leading to increased reliance on glucose. Indeed, glutamine deprivation 
induced glucose uptake in both oeFBP1 and vector control cells. Comparing the two 
cell types, FBP1 over-expression correlates to decreased glucose uptake in all three 
conditions; full DMEM, glucose deprivation followed by 4 hours replenishment and 
glutamine-free DMEM (Fig 11 b). This points out to a general inhibitory effect of FBP1 
on cellular glucose uptake. Especially in glutamine-deprived media, FBP1 seem to 
limit the cells’ compensatory capacity to maximise glucose uptake. Due to the 
increased difference in glucose uptake rate between oeFBP1 and control vector cells 
upon glucose replenishment, I speculated that FBP1 should alter glucose sensitivity 
in cells. To test this, I used the theoredoxin-interacting protein (TXNIP) as a marker of 
glucose sensitivity and uptake. TXNIP is a pro-oxidaton protein that also functions as 
a glucose sensor and eventually mediates a negative feedback loop that slows down 
and regulates glucose uptake. TXNIP expression is mediated by glycolytic 
intermediates on a transcriptional level, and energetic stress leads to TXNIP 
ubiquitination and degradation. Therefore, the more glucose is taken up and 
funnelled towards glycolysis, the higher the resulting TXNIP expression. Following 
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glucose starvation, TXNIP is completely depleted form the cells. In contrast, glucose 
presence in DMEM is enough to maintain a medium level of TXNIP expression 
whereas 2-Deoxyglucose is a potent inducer of TXNIP due to its phosphorylated 
analogue which cannot be further isomerised, and therefore accumulates in the cells 
and drives TNXIP expression (Fig. 11 c and d). Glucose replenishment restores 
TXNIP expression to a level that corresponds to the amounts of glucose taken up 
and phosphorylated. Therefore, TXNIP level makes a suitable marker for glucose 
sensitivity following depletion and replenishment. Compared to unmodified MCF7, 
FBP1 deficient MCF7 cells exhibit higher levels of TXNIP expression both in base-
line conditions (full DMEM) and following glucose starvation/replenishment with 
different glucose concentrations (Fig. 11 c and d). In contrast, the over-expression 
did not lead to as clear and reproducible differences in TXNIP induction following 
glucose deprivation/replenishment. This might in part be due to the fluctuations in the 
levels of FBP1 over-expression as clearly seen when comparing the western blots in 
figures 11 c (lower panel) and 11 e. Consistent with its effects on glucose uptake and 
sensitivity, the absence of FBP1 induces the glycolytic flux. It also leads to clear 
induction of the pentose phosphate pathway whose effects are clearly reflected in the 
increase in reduced/oxidized glutathione ratio. Moreover, the increased lactate levels 
combined with decrease in most TCA intermediates signify an increase in aerobic 
fermentation.  
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Figure 11: The over-production of FBP1 slows down glucose uptake, the deletion thereof 
induces glycolytic flux. a) Glucose uptake in full DMEM (20mM glucose, 2mM Glutamin) measured 
by FACS analysis of cells incubated with 2-NBDG for 4 hours. 5000 cells were analyzed, data 
represents mean-values (n≥4) error-bars (SD). b) Glucose uptake in glutamin-depleted DMEM and 
following depletion and replenishment of Glucose. Glucose depletion (Glu-/+) was done for 16 hours, 
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followed by 4 hours with replenishment at 20mM Glucose accompanied by 2-NBDG. Glutamin 
depletion (Gln-) was done for a total of 20 hours, including the 4 hours of incubation with 2-NBDG. c) 
Western blot of cells lysed following glucose starvation and replenishment. d) Quantifications of the 
western blot bands in (c). Signal intensity of each band was normalised to the corresponding loading 
control (Vinculin) band. e) Western blot of cells lysed following glucose starvation/replenishment. f) 
Heat map featuring metabolomics flux analysis of FBP1-deficient MCF7 cells compared to unmodified 
(WT) MCF7 cells. The data features the binary-logarithmic fold changes in the levels of individual 
metabolites in FBP∆/∆ compared to WT cells.  
 
 
To further verify the correlation between FBP1 expression and glucose sensitivity in 
altered TXNIP levels, I performed western-blots on independent triplets of each 
glucose starvation/replenishment condition discussed above. TXNIP was 
immunoblotted along with FBP1, in addition to pACC and pAMPK as sensors of 
energy stress and mediators of adaptation to nutrient scarcity. In complete glucose 
starvation for 20 hours, AMPK is phosphorylated in both wild type, and FBP1-
deficient MCF7 cells. Acetyl co-enzyme A carboxylase is a direct phosphorylation 
target of phosphorylated (activated) AMPK. Compared to unmodified MCF7 cells, 
BP1-deficient MCF7 show stronger phosphorylation of pACC (Fig 12. A) and very 
slight increase in AMPK phosphorylation. This reflects increased sensitivity to 
glucose deprivation in absence of the FBP1 due to inhibited gluconeogenesis. In 
contrast with glucose abundance, TXNIP expression is diminished upon glucose 
deprivation due to both the absence of glycolytic metabolites and AMPK activation. In 
the glucose-replenished condition, 4 hours of 20 mM glucose following 20 hours of 
glucose deprivation, FBP1-deficient cells exhibit much higher TXNIP levels than 
unmodified cells. This indicates faster response to glucose replenishment in the 
absence of FBP1. In glucose abundant condition, constant incubation with 20 mM 
glucose, FBP1-deficient cells also have higher levels of TXNIP expression compared 
to wild-type cells. This can stem from the increased glycolytic flux in the FBP1Δ/Δ, 
especially the accumulation of glucose-6-phosphate G6P which indirectly induces 
TXNIP expression via interaction to its transcription factors. 
IN other words, knocking out FBP1 renders the cells more sensitive to glucose 
deprivation, as seen by increased AMPK and ACC phosphorylation. However, the 
FBP1-deficient cells also become faster at sensing and taking up glucose upon 
replenishment. Further repetition of these western-blot is required to statistically 
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consolidate these findings, the use of multiple controls and general protein staining of 
membranes should be included to overcome the large deviation in these results.  
 
Figure 12: Western-blots showing the FBP1-related alterations in glucose sensitivity and 
response to glucose starvation in MCF7 cells. a) Full glucose deprivation 0 mM glucose for 24 
hours. b) Glucose replenished condition, 20 hours of glucose starvation followed by 4 hours of glucose 
replenishment 20 mM. c) Full medium 20 mM glucose. All western-blots feature biologically 
independent, simultaneously treated triplets of wild-type and FBP1-knockout MCF7. 
 
 
Figure 13: FBP1 increases oxidative stress and mitochondrial biomass.  
a) ROS accumulation in cells cultivated in full DMEM measured using DHE fluorescence. b) 
Mitochondrial mass in full DMEM measured using the MitoTracker® green probe. c) Mitochondrial 
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inner-membrane potential MIMP measured using JC-1 in cells cultivated in full DMEM. In a,b,c cells 
were analyzed using FACS analysis, the bar-plots feature the fluorescence mean-values of at least 4 
completely independent replicates of 5000 cells each normalized to the non-treated wild-type or 
control vector cells, and error bars represent the SD. d) ROS accumulation in cells deprived of glucose 
or glutamine compared to full medium. DHE-labelled cells were analyzed using FACS (5000 cells 
measured). The bar-plots feature the mean-values of 3 biologically independent parallel replicates and 
error bars represent the standard deviation. e) Mitochondrial mass in cells deprived of glucose or 
glutamine compared to full medium. MitoTracker Green labelled cells were measured using FACS, the 
bar-plots feature the mean-values of at least 3 independent replicates and the error bars represent the 
standard deviation. f) The mitochondrial inner-membrane potential measured using JC-1 in glutamine-
deprived cells vs cells in full medium. 5000 labelled cells were measured using FACS. The bar-plots 
feature the mean-values of at least 3 independent replicates and the error bars represent the standard 
deviation. 
 
III-III-4 Quantitative gene expression analysis upon transient FBP1 over-
expression shows down-regulation of M-phase factors. Cell-cycle validation of 
these findings on a functional levels 
To dynamically assess the FBP1-induced transcriptional alterations I measured the 
transcriptional levels of several genes after 4, 24, and 96 hours of transecting the 
cells with Fbp1. The examined genes were assigned based on predictions from 
observed functional roles of Fbp1, a full gene-expression analysis of MDA-MB231 
with ectopic FBP1 (will follow in the upcoming part of this chapter) in addition to 
genes of interest based on the existing literature. The changes in expression of the 
target genes were quantified relative to the combination of three reference genes; 
beta-actin, vinculin and the ribosomal protein 30 RPL30. As predicted, a stark 
increase in the number of Fbp1 transcripts was observed in the cells harbouring the 
over-expression plasmids at all three time points following transfection. The most 
pronounced effects were found 4 days post-transfection, at which most of the 
examined genes were down regulated in response to Fbp1 over-expression (Fig.14 
a). Exceptions to this were Glutaminase1 and UCH-L1, both slightly up regulated, 
consistently with the findings in other cell-lines to be reported later in this chapter. In 
line with several reports of a multiplex antagonistic effect of Fbp1 towards the 
hypoxia induced factor 1 alpha, hif1α was down-regulated 96-hours post-transfection 
with Fbp1. Fam38a, a proto-oncogene linked to metastasis and poor prognosis [98], 
was also among the markedly down-regulated genes. Contrary to our expectations, 
E-cadherin was also down- regulated upon Fbp1 over-expression despite existing 
knowledge of a correlation of Fbp1 to epithelial phenotype and its reported counter-
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EMT role (Fig. 14 a)[60]. The most prominently down-regulated target is the 
centrosome-associated protein e CENP-E, an essential pro-metaphase protein that 
promotes chromosomal segregation and also an activating factor for the spindle 
assembly checkpoint SAC [99]. In addition to the stark repression of CENP-E there is 
a clear down-regulation of aurora-kinase AURKA, a wide range serine/threonine 
protein kinase found in centrosome and essential for normal chromosome 
segregation (Fig. 14 a) [100]. Both suggest a slow down in the metaphase and 
possibly a slower cell cycle. Indeed, the DNA-content cell cycle analysis of the MCF7 
cells with FBP1 over-expression compared to unmodified MCF7 exhibited significant 
increase of the G2-phase cell fraction on the expense of the G1-phase, which points 
to a slowed down meta-phase in accordance with the aforementioned transcriptional 
observations (Fig. 14 b). 
A thorough interpretation and discussion of the remainder of the genes included in 
this expression in contrast with the results obtained from other cell lines will still 
follow after the characterisation of the behaviour of the other included cell lines in 
light of altered FBP1 expression is fully presented. 
 
Figure 14: FBP1 over-expression induces variable transcriptional alterations and slows down 
mitosis. 
a) relative expression values in MCF7 cells (oeFBP1 vs vector-control) from a qPCR at three time-
points; 4, 24, 96 hours post-transfection. The bar-chart depicts relative expression values of the target 
genes calculated in comparison to a combination of three house-keeping control genes; beta-actin, 
ribosomal protein L30 RPL30, and vinculin. b) Cell-cylce analysis based on DNA-content 
measurement using FACS analysis of properly permeabilised and propedium-iodide stained cells. The 
charts feature the averages of three parallel technical replicates, (N=3) error-bars: SD. 
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III-III-5: MDA-MB-231 degrade the ectopically expressed FBP1, protease 
inhibitors can reverse the process and rescue the ectopic FBP1 expression 
MDA-MB231 cells originate from a metastatic breast tumour. Lacking the hormonal 
receptors and featuring a mesenchymal morphology, these cells are representatives 
of the triple negative breast cancers. As mentioned earlier, this wide category of 
basal-like and metastatic breast tumours also exhibit repressed FBP1. To investigate 
the advantages bestowed on the cells via FBP1 repression, I sought to reverse this 
using stable ectopic over-expression of FBP1 in MDA-MB231 cells. Upon parallel 
transfection of both MCF7 and MDA-MB231 cells, transfected cells were selected 
using Geneticin. The established over-expressions were compared to the cells from 
the same type transfected with an empty vector as a control. Surprisingly, the MDA-
MB231 cells harbouring the FBP1 over-expression vector showed a very minimal, 
almost negligible, amounts of FBP1 compared to the MCF7 cells (Fig 15 a). 
However, real-time PCR showed a clear increase in the level of FBP1 mRNA in the 
MDA-MB231 cells with the over-expression vector (Fig 15 b). Similarly, an increase in 
mRNA was also observed in the MCF7 cells, in which the stable over-expression of 
FBP1 was robustly verified on the protein level. This discrepancy between the 
detected mRNA and the almost absent FBP1 protein in the MDA-MB231 cells is 
suggestive of possible post-translational degradation of the protein, especially 
considering that the protein was successfully detected upon transient transfection. 
Therefore, I probed the levels of FBP1 protein in the MDA-MB231 upon proteasome 
inhibition. Indeed, following 48-hours of bortezomib treatment, FBP1 expression was 
clearly detectable in MDA-MB231 with FBP1 over-expression vector to levels 
comparable to those detected in MCF7, while unmodified MDA-MB231 containing the 
empty vector still lacked any FBP1 (Fig. 15 c9). To further confirm the complicity of 
the proteasome in degrading the ectopic FBP1 and eliminate the potential of non-
proteasomal or indirect effects of bortezomib, I used the more specific MG132 
proteasome inhibitor. A shorter treatment of 24-hour of MG132 or bortezomib was 
sufficient to rescue FBP1 over-expression (Fig. 15 d) and so was a 16-hour treatment 
with a gradient of MG132 concentrations (Fig. 15 d).  
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Figure 15: MDA-MB231 cells degrade the ectopically expressed FBP1. a) Western-blot showing 
the levels of over-expressed FBP1 in MDA-MB231 cells compared to those of MCF7 cells with FBP1 
over-expression or with empty vector. Actin is used as loading control. b) qPCR showing the levels of 
fbp1 transcript in MCF7 and MDA-MB231 cells compared to cells carrying the empty vector. Rpl30 
was used as a house-keeping reference gene. c) Western-blot featuring the levels of FBP1 in 
bortezobmib-treated (48 hours) MDA-MB231 cells with FBP1 over-expression plasmid compared to 
cells harbouring the empty vector. Non-treated MCF7 cells (oeFBP1, vector control) were used as a 
positive reference for FBP1. Vinculin and actin are used as loading controls. d) (up) Western-blot 
showing FBP1 levels in MDA-MB231 cells (oeFBP1 vs vector control) d) Western-blot showing FBP1 
levels in MDA-MB231 cells (oeFBP1, vector control) following 24 hours of bortezomib (BZ) or MG132 
(MG) treatments. Actin was used as a loading control. (Low) Western-blot showing the levels of FBP1 
in MDA-MB231 cells upon 16-hour treatment with a concentration-gradient of MG132. 
 
III-III-6: Analysis of the impact of FBP1 over-expression on the gene 
expression profile of MDA-MB231 cells 
The post-translational elimination of ectopically introduced FBP1 in the FBP1-
negative MDA-mb231 cells, implies that the metabolism of these cells is best 
adapted to the loss of this enzyme and the total absence of gluconeogenesis as a 
pathway. Thus, we assumed that Fbp1 expression should correlate to notable 
alterations in the gene expression programs of these cells. Additionally, we asked 
whether the capacity to degrade  FBP1 is inherent to the MDAmb231 cells or rather 
an acquired trait gained through selection. To address these questions we compared 
the gene-expression profiles of the stably transfected MDA-mb231 cells with oeFBP1 
to those harbouring the same empty expression vector.  
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Figure 16: Discerning the effects of ectopic FBP1 on the over-all gene expression levels in 
MDA-mb231. a) As identified from a full transcriptome analysis: Upper-panel: The most up-
regulated genes in the oeFBP1 compared to empty vector cells. Lower-panel: The most down-
regulated genes in the oeFBP1 compared to empty vector cells. b) Quantitative rt-PCR featuring the 
relative expression (oeFBP1 vs vector) of a selection of genes (identified as top-regulated targets in 
the gene exp. profiling) in MDA-mb231cells. c) Western-blot depicting FBP1 levels in MDA-mb231 
cells (oeFBP1 and vector) upon 4-hour treatment with one of the proteasome inhibitors MG-132 (0.5 
µM) or Bortezomib (50 nM). 
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Among the most transcriptionally up-regulated genes (<2 folds induction) in FBP1 
over-expression cells are those coding for several ribosomal proteins, proteins with 
an ATPase function, inflammation-related factors. Notable among these are also 
several individual proteins including UCH-L1, which plays a role in ubiquitin 
processing, glutaminase, the aldo-keto reductase (converting glucose to sorbitol as 
an initial step in the aldose pathway) and FAM83a, a proto-oncogene participating in 
the signal transduction from EGF-R to RAS/MAPk and PI3k/AKT/mTor. While the 
most up-regulated genes contribute to various functions and pathways, a majority of 
the most strongly down-regulated genes (<2 folds inhibition) are essential for the cell-
cycle progression through the metaphase (M-Phase). Out of 23 top up-regulated 
genes, 15 are involved in cell cycle progression, vast majority of them involved in the 
initiation and progression of mitosis (M-phase) with two genes involved in the 
initiation and progression of DNA-replication (S-phase). Other most down-regulated 
genes are also indirectly involved in DNA-replication; these include two histone 
genes (H2AA3, H2AC), and a DNA-repair gene (Exo1). Other down-regulated genes 
include the key regulatory enzyme of the polyamine biosynthetic pathway ODC1 and 
the ubiquitination enhancer LRIG1. To confirm the link between the over-expressed 
FBP1 and the observed trends in gene-expression quantitative-PCR of a selection of 
the most differently regulated genes identified in the gene expression profiling. In 
addition to the normal (non-treated conditions) the levels of mRNA transcripts of the 
selected target genes were also compared upon treatment with MG-132, a 
proteasome inhibitor that stabilises FBP1 expression (as shown in sub-section II-III-
6). Particularly for the 3 cell-cycle and/or DNA-replication related genes tested, slight 
down-regulation is seen in the non-treated condition. Meanwhile the proteasome 
inhibition further inhibited the expression of AURKA, CENP-E and HIST2H2AC in the 
cells over-expressing FBP1 compared to cells containing the empty vector. The 
mRNA levels of Fbp1 were clearly higher in the OE cells in both treated and non-
treated conditions. The actual increase in the ectopically expressed FBP1 protein 
levels following proteasome inhibition was also verified using immuno-blotting (Fig.16 
c).  
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In order to assess the wider influence of FBP1 on cellular functions and pathways, 
more genes had to be included in the analysis than the initially discussed top 
regulated targets. Therefore, I performed a wider analysis of the impact of FBP1 
over-expression on gene-expression patterns in MDA-mb231 including a larger pool 
of up-regulated (≥1.6 folds) and down-regulated (≤0.65 folds) genes (Figure 17 a and 
b). Using the STRING functional protein association network, two separate 
interaction networks of the proteins encoded by the up-regulated and down-regulated 
genes were made. Comparing the two interaction networks, the most noticeable 
difference is the clear arrangement of the down-regulated genes into an interaction-
rich network (Figure 17 b). At the centre of this network are proteins associated with 
the cell cycle progression; the vast majority are proteins essential for mitosis and 
cytokinesis (M-Phase) these include the centrosome proteins CENP- A,E,M,N, 
aurora kinase A AURK-A and its activator TPX, the kinesin family members KIFs 2C, 
4A, 20A, 20B, 23 and the centrosomal protein CEP55. Besides M-phase proteins, 
several other genes encoding for essential cell-cycle proteins are also seen within the 
aforementioned interaction network. These include, the Cyclin A2 essential for the 
cell cycle progression G1/S and G2/M transitions through activating CDK1 (also 
among the down-regulated genes) and CDK2. Other down-regulated genes include 
the histone cluster 2 (H2AC and H2AA3) in addition to Thymidilate synthetase 
essential for thymidine de-novo biosynthesis and the exonuclease 1 EXO1 essential 
for DNA-mismatch repair. In contrast with the heavy interactions observed between 
the down-regulated genes, the interactions among the up-regulated genes are 
scarce. Therefore no wider conclusions regarding the up-regulation of entire 
signalling pathways or cellular functions could be drawn.  
I next sought to probe the transient effects of FBP1 over-expression on gene 
expression. Protein and mRNA were extracted from parallel cultivated and 
transfected MDA-mb231 and HT-29 cells and MCF7 cells. Both protein and mRNA 
were extracted after 4, 24 and 96 hours from each of the transfected cell lines. Using 
immune blotting the levels of FBP1 protein expression at each time-point were 
probed in contrast to cells transfected with the empty vector. No expression was 
observed in either of the cell lines at 4 hours following transfection. In MDA-mb231 
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cells, successful expression was detected 24, and 96 hours upon transfection. In HT-
29, FBP1 expression was detected only at 24 hours after transfection. Taken 
together with the observations of the proteasomal degradation of FBP1 in stably 
transfected MDA-mb231 cells, these findings implicate that MDA-mb231 and HT-29 
cells are both capable of acquiring the capacity to eliminate the over-expressed 
FBP1. However, a proteasomal mechanism of FBP1 degredation was repeatedly 
shown in MDA-mb231 using proteasomal inhibition to successfully rescue FBP1 
expression. Whereas similar proteasome inhibition failed to rescue FBP1 expression 
in HT-29 cells. The underlying reason can be the discrepancy in the concentrations of 
proteasome inhibitors required for rescuing the ectopically introduced FBP1.  
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Figure 18: a) Western-blots showing the levels of transient over-expression of FBP1 4, 24 and 96 
hours post-transfection and the concomitant levels of CENP-E. Left: MDA-mb231, Right: HT-29.  
b) Quantitative rt-PCR analysis of several top down and up-regulated genes upon FBP1 over-
expression.  
 
Since the gene expression analysis demonstrated tangible and wide-range down-
regulation of a plethora of genes coding for cell-cycle factors, especially M-Phase 
associated genes, upon the ectopic expression of FBP1. I probed the impact of FBP1 
over-expression on the levels of the centromere protein E (CENP-E). CENP-E turned 
out as the most down-regulated gene in response to FBP1 over-expression in the 
full-scope gene expression analysis in MDA-mb231 cells, it stabilizes the interaction 
between the kinetochore and the microtubule and is therefore pivotal for 
chromosomal stability during M-phase and for correct chromosomal alignment on the 
metaphase prior to the anaphase. The immune blotting of protein extracts from 
transiently transfected cells showed a noticeable decrease in the CENP-E protein 
levels in FBP1 over-expressed cells compared to the controls harbouring an empty 
vector. Moreover, the plummeting CENP-E levels perfectly coincided with successful 
FBP1 protein expression as seen in both MDA-mb231 and HT-29 cells (Fig. 18 a).  
Parallel to the immune detection of transiently expressed FBP1, mRNA was 
extracted from similarly treated samples and the top regulated genes from the 
expression profiles of MDA-mb231 cells with stable FBP1 over-expression were 
probed.  
 
 
III-III-7 The ectopic expression of FBP1 inhibits glucose and acidification, 
hinders colony formation and leads to increased mitochondrial mass in MDA-
mb231 
After establishing the stable over-expression of FBP1 in MDA-mb231 and the 
observation of the proteasomal degradation of ectopically introduced fbp1, I sought to 
assess some of the metabolic effects of stable FBP1 over-expression in MDA-
mb231. Unlike in MCF-7 cells, the ectopically expressed FBP1 showed no effect on 
glucose uptake levels measured using FACS analysis of 2-NBDG labelled cells (Fig. 
19 a).  
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I assumed that this discrepancy is due to the very low basal levels of FBP1 
expression in MDA-mb231 cells compared to MCF-7. This speculation is supported 
by the widening gap in glucose uptake between oeFBP1 and vector cells upon 
bortezomib treatment. As previously shown, bortezomib stabilizes and rescues 
ectopically expressed FBP1. Bortezomib treatment increased the overall glucose 
uptake in both vector and oeFBP1 cells (Fig. 19 a). However, the increase was 
markedly smaller in cells expressing oeFBP1 compared to their counterparts 
harbouring the empty vector, leading to an Fbp1-associated significant difference of 
glucose uptake in bortezomib treated cells. Further discrepancy in the effects of 
FBP1 over-expression in redox homeostasis and mitochondrial function was 
observed in MDA-mb231 cells compared to MCF-7 cells. MDA-mb231 with FBP1 
over-expression exhibited markedly depleted ROS levels, as measured by FACS 
analysis of DHE labelled cells (Fig.19 b). Probing the cells with JC-1 hinted at 
diminished mitochondrial inner-membrane potential MIMP upon FBP1 over-
expression (Fig. 19 c). However, cells with FBP1 over-expression bestowed larger 
overall mitochondrial mass, measured using the specific mitochondrial probe 
MitoTracker® green (Fig. 19 d). Most notably, the MDA-mb231 cells show diminished 
colony formation and expansion compared to the control cells with empty vector (Fig. 
19 e). This observation perfectly consists with the aforementioned results of gene 
expression analysis that indicated an overall cell-cycle inhibition especially at the M-
Phase levels.  
 
Figure 19: the effects of stable FBP1 expression in MDA-mb231 cells.  
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a) Glucose uptake in stably transfected MDA-mb231 cells (oeFBP1 vs vector). Glucose uptake was 
compared for non-treated and 24-h 25 nM bortezomib (BZ) treated cells. Glucose uptake was 
measured using FACS analysis of cells pre-incubated with full DMEM with 2-NBDG. 5000 cells of 3 
biologically independent replicates were analysed (N=3, error-bar: SD). b) Basal ROS accumulation in 
MDA-mb231 cells (oeFBP1 vs vector) as measured using FACS analysis of DHE stained cells. 5000 
cells of 3 biologically independent replicates were analysed (N=3, error-bar: SD).  
c) Mitochondrial inner-membrane potential (MIMP) measured in stably transfected MDA-mb231 cells 
(oeFBP1 vs vector). D) Mitochondrial mass measured in stably transfected (oeFBP1 vs vector) MDA-
MB231 cells. For a,b,c&d) 5000 cells of 3 biologically independent replicates were analysed (N=3, 
error-bar: SD). e) Colony forming assay CFA for stably transfected MDA-MB231 cells. 200 cells/well 
seeded initially and incubated for 3 weeks.  
 
 
Consistent with the inhibited glucose uptake observed upon FBP-1 over-expression 
in both MDA-mb231 and MCF-7 cells, the ectopic introduction of FBP-1 into MDA-
mb231 cells reduced the acidification rate in these cells compared to cells transfected 
with the empty vector. Both the pH and the impedance were measured using the 
Bionas flow-through system, allowing the online assessment of the acidification rate 
and adherence of the cells. Initially the acidification rate of the cells with FBP-1 over-
expression was slightly higher than the control cells. However, this acidification rate 
dropped within the first 6 hours and stabilized at 70-80% of that of the control cells 
with the empty vector up to 24 hours after the measurement began (Fig. 20 a). This 
drop in acidification signifies a decrease in lactate production as a result of inhibited 
glucose uptake and glycolysis upon FBP-1 ectopic introduction into the originally 
FBP1-deficient MDA-mb231 cells. Monitoring the impedance showed almost no 
mentionable alterations upon FBP-1 expression indicating conserved viability and 
morphology and similar levels of adherence between the FBP1 over-expression and 
the control cells (Fig. 20 b).  
 
Figure 20: online monitoring of acidification and impedence in MDA-mb231 cells with FBP1 
over-expression using the Bionas flow-through system: 
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a) Acidification rate (%) over time in MDA-mb231 oeFBP1 relative to that of the control cells with the 
empty vector. b) Impedance (%) over time in MDA-mb231 oeFBP1 relative to that of the control cells 
with the empty vector.  
 
 
III-IV: The impact of FBP1 on the responsiveness and sensitivity to various 
metabolic, oxidative and genotoxic treatments 
Various alterations have been associated with FBP1 loss, which raises the potential 
of a changed responsiveness and sensitivity to genotoxic, metabolic and RedOx 
modulating treatments. In consistence with existing literature, our findings indicate a 
correlation between FBP1 expression and the level thereof with the basal levels of 
ROS accumulation. Moreover, our findings indicate an increased antioxidant capacity 
in cells as reflected by the increased metabolic flux through the pentose phosphate 
pathway PPP. Compatibly, we had also observed and reported decreased ROS 
accumulation in yeast upon DNA-damaging treatments in FBP1 knockout strains 
compared to parental ones. Moreover, FBP1 K.O. strains exhibited decreased 
sensitivity to low doses of the DNA-methylating agent MMS.  
Taken together, the aforementioned observations all point out at the potential of 
altered sensitivity to particular treatments in cancer cells upon FBP1 loss. Therefore, 
I chose to test this prospect using the CRISPR-Cas9 stable deletion already 
established in MCF7 cells (MCF-7 fbp1∆/∆) compared to the parental wild-type cells. 
 
III-IV-1: FBP1-loss increases MCF-7 resistance to DNA-chelating agents, in 
addition to slightly improving resistance to direct and indirect inhibitors of the 
topo-isomerase activity 
Since I have shown, using mutational analysis in S.cerevisiae, that the sensitivity to 
treatment with methyl-methanesulfonate MMS correlates to FBP1 expression and 
enzymatic activity. I aimed to probe if FBP1 has similar sensitizing effects to DNA-
methylation and other forms of genotoxicity in MCF-7 cells. Surprisingly, no 
difference in sensitivity to MMS was observed in the SRB cell-survival assay (Fig 21 
a). Since our findings in yeast were primarily dependent on drop-tests, whose results 
are primarily dependent on cell growth rather than survival, I also tested long-term 
colony forming assays to assess any additional growth-dependent differences in 
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MMS sensitivity that might remain obscure in a short-term survival assay. However, 
no substantial differences in sensitivity to MMS between wild-type and fbp1∆/∆. MCF-7 
cells were observed with the colony-forming assay either. (Fig 21 f and g) On the 
contrary, the loss of FBP1 in MCF-7 cells bestowed an increased resistance to the 
DNA-chelating agent cis-platin (almost double the IC50 value) in addition to the direct 
(camptothecin) and indirect (daunorubicin) topoisomerase inhibitors (Fig 21 b,c and d 
respectively).  
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Figure 21: a) b) c) d) SRB survival assays of MCF-7 cells (fbp1∆/∆ vs WT). Cells were fixed 48 hours 
after treatment. Points depict the percentage of cell survival corresponding to each given 
concentration and survival curves were plotted with GrapPad Prism using the sigmoidal non-linear 
regression tool, (N=4, error-bar: SD). f) Colony formation assay of MCF-7 cells (fbp1∆/∆ vs WT) upon 
MMS treatment. Cells were treated with a 2:1 serial dilution of MMS starting with 0.001% (v/v) then 
incubated for two weeks. Resulting colonies were fixed and stained using PFA & crystal violet solution. 
g) Colony formation assay of non-treated MCF-7 (fbp1∆/∆ vs WT). Cells were maintained in non-
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treated full DMEM for 2 full weeks. Afterwards cells were fixed and stained with PFA & crystal violet 
solution.  
 
 
III-IV-2: Absence of FBP1 correlates to increased survival upon oxidative 
treatments 
Considering the correlation between FBP1 expression and increased ROS 
accumulation, I aimed to assess the effect of FBP1 on the sensitivity towards 
treatment eliciting oxidative stress. Cell survival assay showed that FBP1 loss slightly 
improves MCF-7 cells resistance to menadione as reflected by slightly improved 
survival upon treatment. Despite the unchanged sigmoidity of the survival curve, a 
look at the lower platue (corresponding to the higher menadione concentrations) 
suggests improved survival of a small fraction of fbp1 K.O cells compared to the wild-
type population (Fig 22 a). However, the observed difference diminished at the last 
time-point of 72 hours following treatment, suggesting that the slightly improved 
resistance to menadione is temporary. Taken together with the fact that menadione is 
a stable one electron Redox-cycling agent that progressively generates reactive 
oxygen species, this indicates slowed-down ROS accumulation in the fbp1 K.O. cells 
compared to the wild-type cells. High concentrations of ascrobate have been 
reported to exhibit oxidative-dependent cytotoxicity against cancer cells. Similarly to 
menadione treatment, the loss of FBP1 slightly improved cell survival upon exposure 
to high concentrations of ascorbate. Additionally, the absence of FBP1 promoted 
growth induction upon treatment with lower concentrations of ascorbate (Fig 22 b). 
Consistently, fbp1 K.O cells accumulated less ROS upon menadione treatment 
compared to the wild-type cells. Moreover, the over-expression of FBP1 in MCF-7 
cells further increased ROS accumulation following menadione exposure (Fig 22 c).  
 
Results 
  87 
 
Figure 22: FBP1 promotes sensitivity to oxidative treatments.  
a) SRB survival assay of MCF-7 (fbp1∆/∆ vs WT) 24, 48 and 72 hours following menadione treatment. 
Points depict the percentage of cell survival corresponding to each given concentration and survival 
curves were plotted with GrapPad Prism using the sigmoidal non-linear regression tool, (N=4, error-
bar: SD). b) SRB survival assay of MCF-7 (fbp1∆/∆ vs WT) 24, 48 and 72 hours following ascorbate 
(vitamin C) treatment. Points depict the percentage of cell survival corresponding to each given 
concentration and survival curves were plotted with GrapPad Prism using the sigmoidal non-linear 
regression tool, (N=4, error-bar: SD). c) ROS accumulation in MCF-7 cells (fbp1∆/∆ vs WT; oeFBP1 vs 
vector) upon 4 hours of menadione, ascorbate or co-treatment with both. ROS levels were determined 
using FACS analysis of DHE stained cells. 
 
III-IV-3: In spite of unchanged sensitivity to metformin, Fbp1 strongly 
sensitizes MCF-7 cells to a combination of ascorbate and metformin 
Metformin is a biguanide used as a first choice treatment for type II diabetes mellitus, 
its effects are mainly attributed to increasing insulin sensitivity and glucose uptake in 
addition to inhibiting gluconeogenesis in the liver [101]. Metformin is thought to work 
Results 
  88 
as a mitochondrial decoupler by inhibiting mitochondrial complex I. Statistical 
correlation of metformin use to decreased incident of malignancy in diabetics shed 
light on a potential anti-cancer use of this widely prescribed drug[102]. Due to its 
effects on respiration and glucose uptake, I speculated that sensitivity to metformin 
should be affected with altered Fbp1 expression. However, no tangible effect was 
observed between wild-type and Fbp1 K.O MCF-7 cells in their sensitivity to 
metformin (Fig. 23 a and b).    
 
Figure 23: FBP1-loss slightly increases MCF-7 cells sensitivity to metformin.  
a) SRB survival assay of MCF-7 (fbp1∆/∆ vs WT) 24, 48 and 72 hours following metformin treatment. 
Points depict the percentage of cell survival corresponding to each given concentration and survival 
curves were plotted with GrapPad Prism using the sigmoidal non-linear regression tool, (N=4, error-
bar: SD). b) and c) Colony formation assay of MCF-7 cells (fbp1∆/∆ vs WT) upon treatment with 
metformin. Cells were treated with a 1:1 serial dilution of metformin starting with 12.5mM and 
incubated for two weeks. Resulting colonies were fixed and stained using PFA& crystal violet solution. 
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Figure 24: the over-expression of FBP1 intensifies the outcome of ascorbate & metformin co-
treatment.  
 
 
III-V: Fbp1 from yeast to cancer 
 
III-V-1 The decoupling mutation of the yeast Fbp1 almost attenuates the 
FBPase catalysis of the human homolog but partially rescues proliferation of 
Fbp1-deficient MCF7 in glucose deprived DMEM  
Aiming to extrapolate the findings from the mutational analysis of yeast Fbp1 towards 
the human homolog. I mirrored the decoupling mutation from yeast Asn75!Ala75 by 
mutagenizing the corresponding evolutionary conserved residue in the human 
enzyme Asn65!Ala65. To characterize the effects of this mutation, I introduced the 
Asn65 mutant into Fbp1-deficient MCF-7 cells and compared its ability to rescue the 
FBPase catalysis to that of the wild-type Fbp1. I had already established that the 
knockout of fbp1 in MCF-7 cells completely annulled the FBPase activity and 
abolished growth and survival in glucose-free medium (see Fig 9). The 
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immunoblotting verified the successful expression of both the wild-type and mutated 
(Asn65!Ala65) Fbp1 as well as the complete absence of Fbp1 in the MCF-7 fbp1∆/∆ 
cells harbouring the empty vector. Despite being slightly more expressed compared 
to the wt-Fbp1, the mutated Fbp1 exhibited almost diminished FBPase activity (≈10% 
of wtFbp1). The effect of this mutation on the on the FBPase catalysis in human cells 
diverges from that observed in yeast in which the enzymatic activity remains intact.      
III-V-2: despite the presence of mRNA, the yeast FBP1-homologue protein was 
not expressed successfully in cell lines and also failed to replace the 
enzymatic activity of the endogenous homologue 
Aiming to decouple the enzymatic activity of FBP1 from other effects arising from 
non-enzymatic interactions, I attempted to replace the endogenous human FBP1 in 
cell lines with the yeast homologue of the enzyme. Upon transfecting MCF-7 cells 
with the mammalian expression vector harbouring yeast-FBP1 pcDNA3.1-yfbp1, 
successful transcription of yeast-fbp1 mRNA was verified (Fig. 25 b). Nonetheless, 
no correspondent yeast-FBP1 protein was detected, and the yeast homologue also 
failed to restore FBPase activity in FBP1-deficient MCF-7 cells (Fig. 25 b). Hence 
indicating the failure of cell lines to express yeast-FBP1. The situation was similar in 
MDA-MB231 cells, in which no successful expression of yeast FBP1 could be 
confirmed. Neither the wild-type form of yeast-FBP1 nor an inactive mutated from 
S133A could be successfully expressed in MDA-MB231 cells (Fig. 25 e).  
III-V-3 mutating proline 5 in human FBP1 does not rescue the protein from 
degradation in MDA-MB231 cells 
The N-terminal proline in yeast FBP1 has been shown essential for its catabolite-
induced ubiquitination and degradation based on the N-end rule. Therefore, and due 
to the hugh levels of evolutionary conservation between yeast and mammalian FBP1 
homologues, I regarded it possible that the proline 5 residue of human FBP1 (the 
closest proline to the N-terminal) can be essential for the newly observed 
proteasomal degradation of FBP1 in MDA-MB231 cells. Nonetheless, mutagenizing 
human FBP1 to replace proline 5 with alanine P5A did not avert the degradation in 
mda-MB231 cells and akin to wild-type FBP1, the protein was only detected upon 
proteasome inhibition with Bortezomib (Fig. 25 f).  
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Figure 25: The mutated human Fbp1 Asn65!Ala65 and the yeast homolog of Fbp1 fail to rescue the 
FBPase catalysis in Fbp1-deficient MCF-7 cells. a) The quantified FBPase activity measured in total 
native protein extracts.  
b) Immunoblotting of full denatured lysates of MCF-7 Fbp1∆/∆ cells with different forms of ectopically 
introduced Fbp1. c) Relative transcription of yeast-Fbp1 mRNA. d) The row graphs of the enzymatic 
activity assay (a), depicting the increase in the NADPH absorption (Abs340) over time.  e) Western-blot 
showing the lack of yeast-Fbp1 expression in MDA-MB231 cells harbouring the expression vector. f) 
Western-blot showing the impact of bortezomib BZ (50nM) in rescuing the expression of wild type and 
P5A mutant Fbp1.  
 
 
III-VI The loss of Fbp1 bestows improved growth and survival upon MCF-7 cells 
in hypoxic conditions 
Since Fbp1 loss has been demonstrated beneficial for survival of cancer cell in 
hypoxic conditions in both a direct metabolic and indirect effect on gene 
transcriptional manner. I aimed to probe the effects of Fbp1 on the survival and 
growth under hypoxia in the context of the Fbp1 deletion and over-expression system 
established in MCF-7. Akin to previous reports, the absence of Fbp1 conferred higher 
growth and survival upon Fbp1 K.O MCF-7 cells compared to the parental cell line as 
seen in the SRB viability assay. Consistently, dead-cell staining using propedium 
iodide also demonstrated 1 fold decrease in the dead cell fraction compared to the 
wild-type MCF-7 cells (Fig 26 c). The over-expression of Fbp1 added no additional 
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disadvantage to that conveyed by the presence of endogenous Fbp1. These 
observations make it plausible that the full loss of Fbp1, at least in part, promoted by 
the presence of hypoxic niches in the tumour where selective pressure favours the 
absence of Fbp1. Despite the suggested advantage of Fbp1-loss in maintaining 
glycolysis in absence of oxygen and promoting complete reliance on fermentation, 
Fbp1-deficient MCF-7 cells exhibited no increased advantage over the parental MCF-
7 wt cell line when it came to glucose uptake. Fbp1-loss correlated to slightly higher 
glucose uptake under normoxic and hypoxic conditions alike (Fig 26 d).  
 
Figure 26: Fbp1-loss bestows survival and growth advantages onto MCF-7 cells 
under hypoxic conditions. a) Growth curves of WT and FBP1∆/∆ under atmospheric 
oxygen levels. b) Growth curves of WT and FBP1∆/∆ under hypoxic conditions (1% 
oxygen saturation). c) Fractions of dead cells upon hypoxia quantified using FACS 
analysis of PI stained cells (N=3, SD). d) Glucose uptake in MCF-7 cells upon 
incubation in normoxic vs hypoxic conditions (N=3, SD). 
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IV-Discussion 
 
“The best way to have a good idea is to have a lot of ideas”. Linus Pauling 
 
 
In the course of my PhD work I explored the impact of Fbp1 in two different systems; 
the budding yeast and breast cancer cell lines (luminal and basal-like). The main 
commonality between the two systems is the additional effects attributed to Fbp1. 
The impact of Fbp1 is best realized by comparing the Fbp1 -deficient cells to their 
wild-type Fbp1 -expressing counterparts. In yeast the knock-out of Fbp1 produces 
strains with higher resistance to the MMS-induced growth and the inhibition of colony 
formation [94]. Whereas, the absence of Fbp1 in cancerous cells predicts worse 
prognosis, and is linked to faster growth, more extreme glycolytic phenotype and   
invasiveness and metastasis [60, 61, 64, 103, 104]. I aimed to further explore the 
impact of Fbp1 in both systems to reach a common understanding of the roles linked 
to this enzyme.  
The results presented shed light on several aspects of Fbp1 roles in both studied 
models, emphasize previous reports from a new perspective, showcase novel 
observations of the post-translational control of Fbp1 levels and suggest new 
explanations for the observed effects of this enzyme. Although no particular single 
common mechanism has been found, the findings suggest several shared trends 
between the two systems (yeast and cancer cells) that should be subject of further 
investigation. In this section I will present the most important conclusions from my 
work, discuss the implications in light of the existing literature and suggest further 
experimental work to build on the presented findings.  
In an order akin to that of the results section, I will begin with discussing the 
implications of my work on the yeast system, followed by those derived from my work 
on the cancerous cells. Commonalities between the two systems will be pointed out 
whenever appropriate, and then recapped and further elaborated on at the end of this 
section.  
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IV-I The over expression of mutagenised Fbp1 in yeast revealed the possibility 
of decoupling of the enzymatic activity from MMS sensitization 
Via site directed mutagenesis, I individually targeted evolutionary conserved residues 
with structural and functional relevance in yeast [85]. The over-expression of the 
mutated Fbp1 in an array of different genetic backgrounds yielded strains with 
varying levels of FBPase activity, growth and survival upon MMS treatment and 
proliferation rates. Despite the apparent correlation between FBPase catalysis and 
MMS-induced growth inhibition, we identified one mutant that particularly defies this 
pattern and thus uncouples the enzymatic activity from MMS-sensitisation. Replacing 
Alanine for the Asparagine in position 65 yields a mutated Fbp1 that retains the 
catalytic activity but contributes no additional sensitivity towards MMS[85]. This is 
best depicted by plotting the measured enzymatic activity of each mutated Fbp1 
against the quantified growth on MMS-containing agar media, a pattern of inversed 
correlation between growth on MMS-agar and FBPase catalytic activity is observed 
that applies to all tested mutants except Asn65. The exclusion of Asn65 also leads to 
a starkly improved linearity reflected by an increase in the R2 “coefficient of 
determination” value from 0.37 to 0.84 (Fig 28).  
This provides evidence of decoupled enzymatic catalysis from the additional MMS 
sensitization phenotype and suggests that a novel non-catalytic function/interaction 
underlies the additional Fbp1-associated increase in sensitivity towards MMS.  
 
Figure 28 featured in my publication in Microbial Cell ˝ 2017 Ghanem et al.“ [85] 
Figure 28: Asn75 defies the pattern of inversed linear correlation between the enzymatic activity and 
growth on agar containing MMS. Depicted is the linear correlation between the measured enzymatic 
activity of the mutants (see Fig. 3) and the quantified growth on MMS-correlating to each mutant when 
over-expressed in wild-type BY4147 cells. a) Including Asn75 b) excluding Asn75.  
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Moreover, a clear distinction must be made between two different hallmarks of the 
Fbp1-associated MMS-sensitization; 1) Growth inhibition and 2) cellular damage and 
survival upon treatment. The first effect is seen in the spot assays of cells in liquid 
cultures on MMS-containing agar, while the second effect by PI staining and colony 
forming assays of cells treated in the liquid cultures.     
The effect of Fbp1 on cellular growth was observed upon over-expression of Fbp1 in 
both wild type and fbp1∆ genetic backgrounds. Clear difference was also observed 
between wild type and fbp1∆ cells without the introduction of ectopic Fbp1 
expression. In contrast, no differences in cell survival and death were observed 
between wild type and Fbp1-deficient cells upon MMS-exposure. While the ectopic 
over-expression of Fbp1 in cells only leads to increased MMS-associated disruption 
of cell-integrity and survival when the ectopic expression of fbp1 is added to its 
endogenous expression.  
 
IV-II Potential underpinnings of the MMS-sensitising effect of Fbp1: altered 
RedOx homeostasis, gluconeogenesis/glycolysis futile cycling and RAS 
regulation by phosphorylated sugars is considered 
On one hand, the decoupling of the enzymatic activity from MMS-sensitization 
suggests a novel activity related to the mutated Asn75, or modified reaction kinetics 
responsible for the observed decoupling of both effects. On the other hand, the 
observed synergy between the ectopically (wild-type or mutated Fbp1) and the 
endogenously expressed Fbp1 in increasing the MMS-inflicted cell damage, in 
addition to the positive correlation between the enzymatic activity of the mutants and 
the MMS-sensitization (except in Asn75 case) both suggest a quantitative 
mechanism in which the FBPase activity itself, or a by-product thereof is responsible 
for the cellular damage. The former possibility can be an outcome of futile cycles due 
to Fbp1 over-production [105], which would jeopardise the glycolytic flow and tips the 
energy homeostasis, hence limits cells’ ability to repair their DNA and cope with the 
MMS-inflicted damage. As potentially harmful by-products, ROS accumulate in the 
cases of DNA damage including post MMS exposure [94, 106]. It has been 
previously shown that Fbp1 absence in yeast abrogates ROS accumulation upon 
Discussion 
  96 
MMS exposure. My results also speak for a similar pattern, with the over-expression 
of Fbp1 or its active mutants leading to an immediate increase in ROS accumulation 
upon MMS exposure and to a long term ROS accumulation when cells are kept in 
stationary phase. Therefore, FBPase activity seems to correlate to an increased 
oxidative stress [60]. This notion was also postulated in cancer cells, where Fbp1 
presence slows down glycolysis by competing for metabolic intermediates with PFK1, 
hence enforcing an increased reliance on respiration and ROS accumulation as a by-
product thereof [107].  Future endeavours to elucidate the links between Fbp1 
enzymatic activity and its additional MMS-sensitising role should focus on the 
aforementioned possibilities. The screened mutants can be of used for this purpose 
since they offer varying degrees of enzymatic activity. To further highlight ROS 
contribution to increased MMS sensitisation, the correlation between the FBPase 
activity and the amount of accumulated ROS should be quantitatively assessed; 
preferably using various ROS probes with relative specificity for different reactive 
oxygen species. These include: DHE for superoxide, H2DCFDA and boronate for 
hydrogen peroxide and MitoSox for quantification of mitochondrial superoxide and 
thus probing the possible link between FBPase catalysis, respiration and ROS 
accumulation [108, 109]. ROS scavenging also offers a way of investigating the 
causality between the severity of oxidative stress and the observed growth inhibition 
in MMS spot assays. Additionally, the genetically encoded redox sensitive GFPs 
(roGFPs), would provide additional means for elucidating the effects of Fbp1 on the 
intracellular RedOx homeostasis reflected in the GSH/GSSG balance or in H2O2 
levels [110, 111]. My preliminary results using the Grx1-coupled roGFP2 sensor 
indicate higher levels of glutathione oxidation upon MMS-treatment in wild-type y486 
cells compared to Fbp1-deficient ones as indicated by the higher levels of oxidized 
roGFP2 fluorescence (λEx=390 nm). Consistently, the absence of Fbp1 also 
correlates to deminished oxidised roGFP fluorescence in the non-treated samples 
reflecting lower cytosolic GSSG levels in Fbp1-deficient cells. A separate preliminary 
experiment showed that Fbp1-deficient yeast exhibited a stronger fluorescence signal 
for reduced roGFP (λEx=480nm) and a weaker signal for oxidised roGFP 
(λEx=390nm) thus suggesting an enrichment of cytosolic GSH on the expense of free 
cytosolic GSSG hence reflecting larger anti-oxidant capacity in Fbp1-deficient cells.  
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Figure 29: a) Dynamic measurement of the fluorescence levels of oxidised roGFP2 (λEx=390 nm, 
λEm=510 nm) adjusted to the corresponding O.D600 values. Featured are real time fluorescence 
measurements of non-treated and MMS treated wild-type and ∆fbp1 strains.  
b) Dynamic measurements of the fluorescence levels of oxidised and reduced roGFP2 in MMS-treated 
wild-type and fbp1∆ strains adjusted to the corresponding O.D600 values.  
 
It must be clearly stated that the abovementioned results using roGFP are 
preliminary and in no way to be accepted as a stand-alone evidence for the increase 
in GSH/GSSG ratio in light of different Fbp1 expression. Nevertheless, these 
observations add up well to the existing evidence that Fbp1 expression quantitatively 
correlates to higher ROS production as previously reported [94] and also seen in the 
results presented in this thesis (Fig. 7). Moreover, the diminished oxidative stress in 
Fbp1-deficient cells consists with reports of similar observations in cancerous cells 
[60, 107] and also with my findings in ductal breast cancer cells MCF-7, in which both 
endogenous and ectopic expression of Fbp1 increased ROS accumulation (Fig. 7) 
and further sensitised cells to oxidative agents (Fig. 22). Based on the above results, 
GFP-based RedOx sensors can be harnessed for the reliable and dynamic probing of 
the cytosolic RedOx homeostasis and anti-oxidant capacity provided that the results 
get quantified relative to control measurements performed in fully oxidising and 
reducing conditions for calibration. 
To test the contribution of FBP1-associated futile cycling to the growth inhibition and 
increased sensitivity to MMS, lower glycolytic intermediates such as pyruvate in 
addition to amino acids that can feed into the TCA can be provided in the culture 
medium in an attempt to annul the Fbp1 associated MMS-sensitisation by 
circumventing the proposed futile cycling in the upper glycolytic pathway [105]. This 
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approach is especially interesting in combination with ectopic over-expression of 
Fbp1 that is more likely to produce futile cycling than the endogenously expressed 
levels. The over-expression mutants with gradually increasing activity can also be 
used as a system of controlling the severity of the potential futile cycling.  
Very recent work on RAS regulation by glycolytic intermediates suggested an 
agonistic effect of fructose 1,6 bisphosphate on RAS via the guanosine nucleotide 
exchange factors GEFs Cdc25 and Sdc25 (homologs of the mammalian RAS GEF 
SOS1) [112]. This suggests a novel connection between Fbp1 and RAS regulation 
via F1,6bP, the substrate of Fbp1 and brings new light to Fbp1 as an anti-proliferative 
regulator. The absence of Fbp1 should conceivably lead to an accumulation of its 
substrate F1,6bP and hence RAS over-activation. Therefore a mechanism in which 
the absence of Fbp1 sustains enough RAS activation upon MMS is very plausible in 
theory. In presence of glucose, Fbp1 should have no noticeable effects on the 
abundance of F1,6bP due to its glucose-mediated transcriptional repression and 
proteasomal degradation [21, 89, 113, 114]. However, MMS treatment seems to 
readily engage Fbp1 by overcoming its glucose repression [94]. The growth inhibition 
on MMS in presence of endogenously expressed Fbp1 can be assumed a protective 
mechanism especially that it comes at no cost on cells’ integrity and survival. MMS 
sensitivity in yeast has been shown to depend upon glucose abundance, and the 
enzymatic activity of both GAPDH and PYK, (lower glycolytic enzymes) was inhibited 
4 hours upon treatment [106]. Altogether this suggests a potential role of the 
accumulating upper glycolytic metabolites, including F1,6bP, as modulators of the 
outcome of MMS treatment in S. cerevisiae. Whether differential RAS activation by 
F1,6bP could offer an explanation to the link between Fbp1 and the response to 
MMS treatment intriguingly remains an open question to be answered. The 
elucidation of this potential link should make use of CDK25 and SOS1 mutants with 
impaired interaction to F1,6bP, such mutants have been already established and 
reported to abolish the F1,6bP activation of RAS [112, 115, 116]. The mutation library 
of Fbp1 presented in this thesis is also a suitable tool for the above-suggested 
endeavour since it offers a way of titrating Fbp1 activity and thus the availability of 
intracellular F1,6bp.  Additionally, probing the effects of the decoupling mutant Asn75 
in light of various RAS backgrounds would be of additional interest, since the effect of 
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F1,6bp on RAS is not obviously concentration-dependent suggesting that the impact 
of different enzyme dynamics of Fbp1 on RAS activation could vary unpredictably.  
Altogether, all the aforementioned potential mechanisms of Fbp1-dependent MMS 
sensitisation rely upon metabolic, oxidative or signalling components common 
between yeast and mammalian cells. Indeed, many of the observed effects of Fbp1 
that can underlie the MMS sensitisation have also been observed in cancerous cell 
lines including the results presented in this thesis.  
Increased oxidative and metabolic stress has been observed upon Fbp1 introduction 
to cell lines. Impeded growth, proliferation and colony formation are also common 
hallmarks between yeast and cancer cells harbouring ectopic expression of fully 
functional Fbp1. Consistently cells with Fbp1 over-expression demonstrated multiple 
signs of glycolytic inhibition. Hence substantiating the notion that Fbp1 is central for 
counteracting the Warburg effect and the resulting rapid proliferation. 
 
 
IV-III Fbp1 abrogates glucose uptake and glycolysis in cancer cells and 
promotes a respiratory metabolic program 
Recently Fbp1 loss has been indicated as a detrimental event in the metabolic 
reprogramming essential for cancer initiation or later gain of invasive and metastatic 
properties [60, 61, 64, 107]. The findings of this thesis fall in line with the reported 
effects of Fbp1 on cancer cell metabolism. These could be summed up as reduced 
glucose sensitivity and uptake, slowed down glycolysis and reliance on respiration 
also resulting in higher ROS levels and oxidative stress. An examining view of the 
existing body of knowledge on Fbp1, and its repression in various types of cancers 
suggests two distinct means by which Fbp1 excerpts its metabolic “tumour 
suppressor” effects. The first is a direct consequence of Fbp1 catalytic activity. By 
splitting F1,6bP into F6P and inorganic phosphate, the enzyme directly contributes to 
the intracellular abundance of 6-phospho hexoses [117]. Additionally, F1,6bP has an 
activating role on PKM2 by stabilising its tetrameric enzymatically active form. By 
depleting its own substrate F1,6bP, Fbp1 indirectly deactivates PKM2 by hindering its 
tetramer formation [118, 119]. PKM2 inactivation leads to a slowed down 
dephosphprylation of PEP and thus an increased accumulation of lower glycolytic 
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intermediates in addition to the above mentioned phospho-hexoses accumulation. 
The accumulation of glycolytic intermediates has an inhibitory effect of glucose 
uptake in part by promoting the expression of the theoredoxin interacting protein 
TXNIP. Both G6P and GA3P trigger the nuclear translocation of MondoA and 
ChRheb, which subsequently trigger TXNIP transcription [120, 121]. TXNIP then 
closes the negative feedback loop by triggering the internalization and subsequent 
degradation of GLUT1 and thus inhibiting overall glucose uptake [122]. Consistent 
with the suggested mechanisms, my findings robustly show an inverse correlation 
between Fbp1 levels and TXNIP in various contexts, especially upon glucose 
replenishment. Seen in light of the inhibited glucose uptake in presence of Fbp1 and 
the increasing difference of TXNIP expression upon glucose replenishment, the 
Fbp1-associated down-regulation of TXNIP is best explained as an outcome of 
inhibited glucose uptake and not as a cause thereof.  
The metabolic quantification presented in this thesis also suggests an Fbp1-elicited 
overall down-regulation of glycolysis and and a higher intracellular lactate levels in 
Fbp1-deficient cells. The predicted increase of hexose-phosphates as a result of 
Fbp1 activity can grant basis for the assumption that Fbp1 supplies the pentose 
phosphate shunt with an abundance of G6P. However, the findings in this thesis defy 
this notion by clearly depicting an increase of flux through the pentose phosphate 
shunt upon Fbp1 deletion. Moreover the Fbp1-deficient MCF-7 cells exhibit higher 
levels of upper glycolytic intermediates compared to the parental MCF-7 cells. The 
apparent contradiction in these observations is simply resolved by the clear 
observation that both endogenous and ectopically introduced Fbp1 significantly 
reduce glucose uptake and sensitivity. Hence, the inhibited glucose uptake due to 
Fbp1 over-expression translates to a decreased flow through both glycolysis and 
pentose phosphate pathway, and the contrary applies to Fbp1-loss. 
 
IV-IV The existing evidence suggests an anti-tumour outcome of the indirect 
inhibition of PKM2 by FBP1 in addition to competition between the two 
proteins as transcriptional co-activators  
As part of their metabolic reprogramming, cancer cells favour the embryonic pyruvate 
kinase isozyme M2 PKM2 over the M1 isozyme predominantly expressed in 
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differentiated tissues[123]. The flexible post-translational regulation of PKM2 and its 
non-enzymatic roles, including as a transcriptional co-activator, bestow cancer cells 
with metabolic advantages that support their special demands of precursors to fuel 
their rapid proliferation [124, 125]. PKM2 is subject to allosteric regulation by fructose 
1,6 bis phosphate F1,6bP, the substrate of Fbp1. Binding of F1,6bP promotes an 
active tetrameric configuration of PKM2[118]. Hence Fbp1 is speculated to have an 
indirect inhibitory effect on PKM2 by depleting F1,6bP.  
The interplay between Fbp1 and PKM2 has been highlighted as part of Fbp1 tumour-
suppressor and anti glycolytic effects [60, 107]. This is despite the fact that idle 
PKM2 has been assumed advantageous for fuelling cancer metabolism and 
proliferation in various cellular and animal studies [126, 127]. The inactive PKM2 is 
thought to allow the funnelling of glycolytic intermediates for anabolic processes 
including amino-acid synthesis, especially serine [128], and the pentose phosphate 
shun t[129]. In addition, the enzymatically inactive dimer form of PKM2 has been 
demonstrated to translocate into the nucleus, where it operates as a transcriptional 
co-factor of several regulators including β-catenin and Hif-1α [130, 131], through 
which PKM2 exert a self-propagating feedback loop which ends up in further 
activation of Hif-1a and further up-regulation of glycolytic enzymes including PKM2 
itself [132, 133]. Nevertheless, the two above listed mechanisms fall short of 
describing the particular outcome of Fbp1 related inhibition of PKM2. The results 
presented here, consistently with earlier research on Fbp1 loss in breast cancer [60], 
demonstrate an increased flux through both glycolysis and the pentose phosphate 
pathway. Thus suggesting an over-all increase in the flux over glucose catabolic 
pathways in Fbp1 knockout cells as a result of an overall increase of glucose uptake. 
To ensure that the effect of Fbp1 on PKM2 holds true in the stable cellular system I 
established, I verified the increased activity of PKM2 in Fbp1-deficient MCF-7 cells 
compared to their wild-type counterparts (Fig 30). 
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Figure 30: Fbp1 deletion causes PKM2 induction.  
Left) PKM2 induced decrease in NADH absorbance over time. Right) The relative activity of PKM2 in 
the native lysate of Fbp1-deficient MCF-7 cells compared to MCF7-wt.  
 
Moreover, PKM2 was reported to exhibit a predominantly monomeric conformation in 
Fbp1 positive breast cancer cells, as opposed to the active tertrameric form seen in 
Fbp1-deficient cells[60]. It is the dimeric form of PKM2 that is deemed to elicit co-
transcriptional regulation promoting cancer metabolism and proliferation [125, 132, 
134]. Hence the predominance of the monomeric inactive form in presence of Fbp1 
grants another ground for assuming the Fbp1-induced PKM2 inactivation of no 
particular advantage for tumour metabolism.  
Fbp1 and PKM2 seem yet to also collide as co-transcriptional regulators with 
opposite effects. This prediction arises from the recently described inhibitory 
interaction between Fbp1 and and Hif1a[61]. The described interaction involves the 
translocation of Fbp1 into the nucleus, where it subsequently binds to Hif1a and 
inhibits its transcriptional effect and, thus impedes the metabolic rewiring required for 
the metabolic reprogramming required to support rapid proliferation [61]. The 
inhibitory interaction of Fbp1 to Hif1a is non-enzymatic since it was exhibited to work 
using inactive truncations of Fbp1[61]. Consistently the findings of this thesis 
demonstrated that Fbp1-loss bestows cells with an increased tolerance to 
???whatand improved survival upon hypoxia.  
Taken together, evidence has been presented for non-enzymatic interactions of Fbp1 
and PKM2 to Hif1a with either an inhibitory or a co-activation outcome, respectively 
[61, 132]. This suggests a potential competition between Fbp1 and PKM2 in binding 
Hif1a. It is plausible that Fbp1 can inhibit PKM2 co-transcriptional cancerous activity 
by preventing its interaction with Hif1a or/and other transcriptional regulators. 
Intriguingly, the over-expression of Fbp1 under a constitutively induced promoter was 
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sufficient to abrogate EMT in luminal breast cancer cells [60]. Normally, Snail 
expression is sufficient to induce EMT in luminal cell lines with E-Cadherin, Fbp1 and 
several other targets being repressed in the process. The continued expression of 
irrepressible Fbp1 (constitutively expressed) prevented EMT and maintained E-
Cadherin expression [60]. Recently it has been demonstrated that PKM2 participates 
in the epigenetic silencing of E-Cadherin in EMT contexts by interacting with the co-
transcriptional repressor TGIF2, which subsequently recruits histone deacetylases to 
E-Cadherin promoter [135]. All this makes it more imperative to thoroughly 
investigate the multiplex interaction between Fbp1 and PKM2 on metabolic and 
transcriptional regulation levels. To achieve this, the impact of Fbp1 on PKM2 
conformation and activation state and the resulting effects on cellular metabolism 
should be examined in cells exhibiting various levels of PKM2 activity and Fbp1 
content. In addition, assessing the adversary effects of FBP1 on the transcription of 
characterized targets of PKM2 co-activation role should help determine if Fbp1 
competes with PKM2 for binding Hif1α and/or other transcriptional regulators.  
Finally, it is also apt to hint here that G6PD, the entry enzyme to the pentose 
phosphate pathway, also demonstrated higher enzymatic activity in Fbp1-deficient 
yeast, especially in the context of MMS treatment that increases the demand on 
ribose phosphates for de-novo nucleotide synthesis. Therefore, the overall 
antagonistic effect of Fbp1 on glucose catabolism seems rather general and 
evolutionary conserved.  
Further unravelling of the interaction between Fbp1 and PKM2 is imperative for a 
better understanding of the metabolic reprogramming essential for cancer initiation, 
progress and acquisition of invasive properties.  
 
IV-V Fbp1 as an indirect ROS inducing factor 
It has become widely accepted that reactive oxygen species transcend their 
previously assumed purely harmful role to actively participate in cell signalling [136, 
137]. 
Diverse roles have been attributed to ROS including the participation of H2O2 as a 
secondary transducer of various extracellular growth signals including insulin EGF 
and VGEF[138]. Additionally, ROS accumulation and DNA damage show reciprocal 
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feedback with unchecked accumulation of ROS leading to DNA damage and ROS 
production being an essential part of the cellular response to DNA damage [139]. 
Further studies illuminated the mechanism by which DNA damage triggers ROS 
production. The histone H2AX conveys the DNA damage signal to NOX1, which 
produces reactive oxygen species that are determinant of the outcome and the cell-
death and senescence decisions[140]. MMS treatment is no exception to other types 
of DNA damage in inducing high levels of ROS that are detected in yeast within 1 
hour of exposure [85, 94, 106]. Intriguingly, the absence of endogenously expressed 
Fbp1 abrogated ROS accumulation in yeast in contexts of MMS treatment and 
chronological aging[94]. Consistently, Fbp1-deficient MCF-7 cells exhibited 
diminished basal ROS levels compared to the parental cell line while the ectopic 
over-expression of Fbp1 in the same cell line correlated to increased ROS 
abundance. Moreover, Fbp1 over-production correlates to diminished tolerance to 
oxidizing treatments. Altogether, this indicates Fbp1 as an important mediator for the 
regulation of ROS production. The effect of Fbp1 on ROS stems from its respiratory 
inducing effects as a result of the direct and indirect metabolic reprogramming roles 
discussed above.  
Therefore, it is very plausible that the loss of Fbp1 relieves the intracellular oxidative 
stress, thus allowing a wider tolerance margin towards oxidative agents. This state of 
relieved oxidative stress permits cells with damaged and unstable DNA to continue 
proliferating due to the lack of ROS signalling required to engage apoptosis or 
senescence[140]. This last point also sheds light at a potential mechanism by which 
the loss of Fbp1 can also promote cancer initiation and recurrence.  
In accordance with the literature, the results of this thesis suggest an evolutionary 
conserved pro-oxidant role of Fbp1 as a result of increased respiration. Hence future 
work should focus on the premise of Fbp1 and gluconeogenesis as pro ROS 
signalling components. The impact of Fbp1 activity on ROS can be relevant to its 
observed roles including the MMS-sensitisation effect in yeast as suggested by the 
observation that direct ROS scavenging using TEMPO rescued the growth on MMS-
containing agar[94]. While the enzymatic activity of Fbp1 could explain the increase 
in ROS as a result of increased respiration, other indirect ways as result of non-
catalytic interactions cannot be ruled out, especially since similar interactions have 
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been reported in human cancer cells. The screened mutants library and especially 
the decoupling mutant would make a good tool for probing the relation between the 
catalytic activity of Fbp1 and ROS production and the general intracellular RedOx 
homeostasis.  
 
IV-VI Evidence of ectopic Fbp1 slowing down the cell cycle hints at metabolic 
regulation of cell cycle progression 
In their quest for division, cells must ensure sufficient supply of energy and metabolic 
intermediates required for the biosynthesis of macromolecules for the daughter 
cells[141]. Hence the cell cycle and cellular metabolism are tightly synchronised so to 
supply the energy and biomaterial necessary for DNA replication and cell division in 
general[142, 143]. Introducing Fbp1 into the Fbp1-dificient MDA-MB-231 cells 
correlated to a wide-scale transcriptional inhibition of a variety of cell cycle related 
factors. This sort of gobal inhibition of Fbp1 has not been previously reported and 
therefore sheds new light on the anti proliferative impact of Fbp1. The moderate 
transcriptional inhibition of a majority of mitotic factors in addition to considerable 
number of G1/S factors could be seen as an outcome of impeded cell growth and 
proliferation upon Fbp1 introduction. In a slowly proliferating population, less cells are 
likely to be engaging in mitotic events and therefore the expression of the factor 
required for this phase is diminished. Nevertheless, particular aspects of the 
reciprocal regulation between metabolism and the cell cycle suggest potential 
mechanisms by which Fbp1 could affect certain cell cycle components. These 
include the up-regulation of the thymidylate synthase by the E2F transcriptional factor 
being subject to ROS regulation of the latter[144, 145]. Our analysis indicated 
thymidylate synthase as one of the most down regulated targets upon Fbp1 
expression in MDA-MB231. This suggests an indirect inhibitory effect of E2F by Fbp1 
due to the Fbp1 induced alterations in ROS production and accumulation. 
Intriguingly, the MDA-MB-231 cells represent the only context in which the ectopically 
expressed Fbp1 diminished ROS accumulation, a very unexpected result that 
possibly relates to ectopic Fbp1 being subject of proteasomal degradation in MDA-
MB-231 cells. Moreover metabolism impinges on the cell cycle more directly via 
signalling queues that sense nutrient and energy scarcity and relay an off signal to 
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the cell cycle regulators. A prone applicable example is AMPK sensing critically 
elevated AMP (or ADP) and phosphorylating the tumour suppressor p53 (Ser15) that 
conveys the signal to p21, which subsequently imposes G1/S cell cycle arrest[146, 
147]. Therefore, it is plausible that the metabolically disadvantageous enforced 
expression of Fbp1 could elicit G1/S cell cycle arrest akin to glucose scarcity or 
deprivation. Pondering this novel observation of Fbp1-associated cell cycle inhibition, 
PMK2 also pops into the picture since its nuclear non-catalytic activity modulates the 
workings of M-phase proteins responsible for efficient and error-proof chromosomal 
segregation[148]. Since Fbp1 indirectly affects the tertiary structure of PKM2 by 
consuming F1,6bP[60], it also inevitably affects its nuclear sub-localisation and thus 
its cell cycle related function as well.  
 
IV-VII Fbp1 and gluconeogenesis regulation from yeast to cancer, evaluation of 
the inter-species and heterologous approach 
The notion of the high evolutionary conservation of Fbp1 leading to similarities in the 
regulation in yeast and cancer cell lines is central to this thesis. Indeed, the high 
degree of similarity in the glycolytic pathway, and the aerobic fermentation associated 
to both cancer cells and yeast are all valid reasons to place high values at the 
predictive capacity of the findings in yeast for the situation in cancer cells.  
Nevertheless, the effects of the particular decoupling observed in the yeast mutation 
N75A did not simply extend to the corresponding mutation of the human enzyme 
N65A. This is  evident in the almost completely diminished enzymatic activity of this 
mutant in the human enzyme compared to the almost intact enzymatic activity 
observed in  the corresponding mutation in yeast. Despite the disparity of the effects 
of this peculiar mutation on the enzymatic activity, the general FBP1-associated 
effects in both yeast and cancer cells exhibited comparable tendencies.  Both yeast 
and cancer cells exhibited slower growth upon ectopic FBP1 expression, in addition 
to hallmarks of oxidation stress and imbalanced redox. Moreover, this work also 
demonstrated initial evidence of reduced sensitivity towards some genotoxic agents 
in FBP1-deficient, most prominently cis-platin.  Nevertheless, Fbp1 absence made no 
difference for MMS sensitivity in the tested MCF-7 cell line. MMS induced DNA 
damage is mostly reversed by base excision repair BER mechanisms[94]. Therefore, 
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the reported deviation between yeast and mammals in the BER mechanisms 
including the absence of two factors can offer an explanation for the absence of the 
Fbp1-related differences in MMS-sensitivity in human cancer cells. Interestingly, the 
findings in this thesis in addition to earlier works provide evidence that Fbp1 deletion 
mitigates the burst in ROS shortly after MMS exposure. Meanwhile, mammalian BER 
has been reported especially superior to yeast BER in handling oxidative DNA 
damage[60, 149]. Therefore, I speculate that the superior BER system in human cells 
prevents the translation of Fbp1-associated oxidative stress into an increased 
sensitivity to MMS-induced DNA damage.  
Perhaps the biggest advantage of the dual yeast/human-cells system is that it 
inspired to consider the possibility of previously unreported post-translational 
degradation of Fbp1 in human cancer cells. In this thesis, I described a first-hand 
observation of Fbp1 degradation when ectopically expressed in the Fbp1-negative 
basal-like breast cancer cell line MDA-MB231. Although no reports on any 
proteasomal degradation of Fbp1 in cancer existed at that point, my familiarity with 
catabolite degradation of the yeast homologue enabled me to consider this possibility 
in cancer cells. Later reports of proteasomal degratation of Fbp1 in hepatocellular 
carcinoma added further confidence to my observation[95]. Nevertheless, my efforts 
have yielded no evidence for the same ubiquitination machinery implicated in Fbp1 
degradation in hepatocellular carcinoma also underlying my observation in breast 
cancer cells. None of the three genes TRIM28, MAGE-A3 or MAGE-C2 showed any 
peculiar variations in their levels of expression between MDA-MB231 cells and MCF-
7 cells or in MDA-MB231 cells upon Fbp1 over-expression. While this does not 
completely rule out the complicity of these factors in the observed degradation in 
MDA-MB231 cells, it at least signifies the potential of other mechanisms. Recently, 
the GID ubiquitin ligase, a complex with 8 evolutionary conserved components, has 
been showcased to mediate the catabolite degradation of Fbp1 and other 
gluconeogenic enzymes in yeast[21]. Hence further work to understand the 
mechanism underlying the ubiquitination proteasomal degradation in breast cancer 
cells and cancers in general, should also consider the possibility of evolutionary 
conserved pathways.  
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In retrospect, I view my experience in addressing my topic in a yeast/cancer dual 
system favourably. While the effects of mutagenising particular evolutionary 
conserved residues might vary between the two systems, it is no surprise that overall 
mechanisms exhibit high similarity. While the evolutionary conservation of large 
segments of metabolic pathways, DNA damage and repair mechanisms should be 
kept in mind when pursuing such approaches, extra attention should be dedicated to 
disparity between the two systems so that deviations in outcomes could be predicted 
and explained. The most unique aspect of this approach is viewing the cancer-
associated metabolic reprogramming and the Warburg effect as a regressive 
phenomenon that awakens ancient ‘selfish’ and ‘originally unicellular’ metabolic 
programmes in a multi-cellular organism with well known destructive outcomes [45, 
46] 
This view has been recently echoing in the milieu of cancer research[150, 151] and 
while it does not yet provides no direct contribution to treatment, it offers a fresh and 
dynamic framework of a wider comprehension and discussion of the evolutionary and 
metabolic aspects of malignancy that can hopefully contribute to a more robust and 
total approach against cancer. 
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V-Conclusions 
The results presented in this thesis emphasise the reported impact of Fbp1 on 
response to genotoxicity in yeast, and support its antiproliferative role in both yeast 
and cancer cells. In light of various recent reports on Fbp1 repression in various 
tumours, this thesis further reiterates Fbp1 as a probable tumour suppressor with 
metabolic and non-metabolic functions. This overall conclusion is supported by the 
following experimental observations:  
" Despite the general correlation between the enzymatic activity of Fbp1 and the 
previously described MMS-sensitisation, the mutational analysis of Fbp1 in yeast 
revealed the possibility of decoupling the enzymatic activity from this additional 
effect.  
" The ectopic expression of Fbp1 slows down the growth of both luminal MCF-7 
and basal like MDA-MB231 breast cancer cells. 
" In cancer cells, FBP1 expression changes glucose sensitivity and inhibits glucose 
uptake, glycolysis and pentose phosphate pathway.  
" Fbp1 is essential for survival in glucose free DMEM.   
" The ectopic introduction of Fbp1 in the originally Fbp1-dificient MDA-MB231 cells 
correlated to a generalised transcriptional inhibition of cell cycle factors, especially 
M-phase factors. 
" Basal-like breast cancer MDA-MB231 cells developed the capacity to 
proteolitically degrade ectopically expressed Fbp1 upon long-term selection of 
successfully transfected cells.  
" Fbp1 expression exhibited pro-oxidant roles in both yeast and cancer cells, 
manifested in higher base-line and post-MMS ROS levels, reduced reductive 
capacity, and tolerance to oxidative treatments.  
These summarised findings suggest variable sources for the observed effects with 
Fbp1 and hence warrant further investigation into the mechanisms underlying these 
observations. Further work on this should consider two major potential sources of 
Fbp1 antiproliferative impact. The metabolic effects, mainly stemming from 
alterations in the altered availability of phospho -hexoses and the non catalytic 
protein-protein interactions, some of which have already been implicated in recent 
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reports. Moreover, the potential for proteasomal degradation of Fbp1 should be 
further investigated, especially in precancerous contexts in which the gradual ablation 
of Fbp1 could prompt tumour initiation or an increase in tumour aggressiveness. 
Exploring these possibilities will be essential for devising potential prevention 
strategies relying on the prevention of Fbp1 loss or ambitious treatment approaches 
based on the later de-repression/prevention of post-translational deactivation of 
Fbp1.  
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